Skip Navigation
Skip to contents

Urogenit Tract Infect : Urogenital Tract Infection

OPEN ACCESS

Articles

Page Path
HOME > Urogenit Tract Infect > Volume 15(3); 2020 > Article
Original Article Clinical Characteristics and Antimicrobial Susceptibility of Elderly Women with Acute Pyelonephritis
Ji Kang Yunorcid, Woong Bin Kimorcid, Sang Wook Leeorcid, Kwang Woo Leeorcid, Jun Mo Kimorcid, Young Ho Kimorcid
Urogenital Tract Infection 2020;15(3):71-78.
DOI: https://doi.org/10.14777/uti.2020.15.3.71
Published online: December 31, 2020

Department of Urology, Soonchunhyang University Bucheon Hospital, Bucheon, KoreaJFIFddDuckydqhttp://ns.adobe.com/xap/1.0/ Adobed     ! 1AQa"q 2#w8B36v7XRr$9bCt%u&Ws'(xy4T5fH  !1AQaq"2B Rbr#u67Ѳ3sTt5v8Sc$4ĂCÔ%UӅFV ?_Aנj- H>>,m*>fzp"TrKkr^r.|_&]|*vPuܶvoQ1mwVJUhu-I"=LniAƕ8"۲ k*ҿ[yu:.vUQ+)%F DHyVBk>Hy8jݹ q~9D4KRmzQ)^ʔ.J%k_tVi5NTjg!'ky|5asOȻ)R۸ߩFMԿ3L4j6dڜ#NIwUF]JqB/(FafJRzq3\G՛ ?~\ 6)6W4m[O^L0E&rRMض*C .]Unl-1 1r#Rj/&QɈ׉˩s6Rj=5Tg.y.·Pӡ:JJS:C8-2u]d&vUz;7p9 5VnL֢"y)">iי(IDDd| Yj0; LRfS:ktYK%*N2^m|&dğth":ey)uPQZW)gcC3Pv&MMWd&Ŵ۲mvTRoժM03*F3Yd6\8,\hݻ kߔi<k NTwSԪmljj[>->ptU%'LR>&EBH$MQAUx[$Z6vi&_a.KIQ{hyƒ j"JOC9eFҝfj;˚Ω<[3_m% lQ@4g=5$(J]Yc-OMq<Ǎ wSzڗ)k$7VIP붾ͯnV+卵*t]iЎD31~SA1éC2u)ʼnQn-Uoi3:grI8ؓWm*G zܕ)ZקJ}Y YlGeJ6cB2I NS3Q>k=KTBT]W6+SOXQgGR? telˊ%-Re\hѯ2TF"C/OJΩ6r[N.0{SpljjX1“jOsӥ;ҭhe}xu`Ք&.)yO̒ Fߑ.$Qw;9Iw2o+RVJMSOj[SoҌZ%;`d$blQ{Ro{Imڌ>3egf\O֝Uzx"䢸g+mv%Gʆ:|V[N'&ס-ޝ'kfE|K,G&˳98Juin/\\Qݿ̋v~Ǩ!rtWU d|E߫R4d}.qPw*Ӭv5YEcn~f5c%MTMkb-F>5JT,})QHg%{("ӔȸWMsYyWNRrkkJr0XドnͫT}r-jj,Ŕʍ\Q2Ri>v$5!]"JB2WɅ)]VԜUc8i|.jeRO6^V.¸ Q&#|ܶ-*uOG%JAtRZRr]FFG\۩w+?'zչSѧt jz>KW&ot{7P&2D;&\\>Q2JzܗAKSfeNn[jRrԕf6,q,F1tRfԗ>vֶևj-&R'Zi2=xv~Elbsvm8=ӛ"ū񕜈BȩlWau[]ٷBߨF~J!|Ipr3R̴#Yp)={7:G{+:\W}n|Q#%)7^-h"Ƒq:M*%J&$T軨I333׎g_- ucBwwjp[6i25$̏bU’ٱRv?G\~#Iͪb7<<}Ezt" q_Inw,7-d,G÷%T* Wg1"䥱kq/A.,_KhqŒxwvo u2ۥۧ.bQ}XκA$֣ +K״ZUNmڸII{.v{5z5ѮRme[moyƾd~cRݾK'j.\i&/S6f|b=5: p!6i_ 4j6=.si˧eƾtS^c.Y^RJVS-Vi3,esi08?H$GvZgg?gi䤟2adw릿:"۪lkSN>q-4kI܋ێe̊qۅgDoѨ9; #T.Q;7#~_Ufstb_'w~Xw1Xk,vcOt._}v}8"(4Z\ۘgk?J?bm_c!g{HZV]Fkk%~gEt)b秴vΰB|꽸}mp~E6ݹv;7P٤v+ri*3Ԣ|'O14_~7nP{7ZU\Vű[ +7󖱅o#:ǥŬ\|3r%TJX]V7ez¨Y]lc|O3V! R zbJ'PnGqVJ"19WVeOF埜EaEJωqCN5Z g-9[S<$sUK5b|7sn\7x qmv##FF\ w[=-43$^ooVSiXօv7iB۴yg>]Vf"r$J3""32!Zh[K%7GvNLs+4nB/B{vlsobJaҺJR:0g%&zR\ S3T[&ִor*ⷳc3ʊO[iozW٨%$gn:ܶWwFBԹjHP&z u&F2\f;ipW73 [; '_̽b;vib!oec dC-tS__$Xs]l9&z$2/N>%'[}b{h/{`{Ji׉׏ YJB/X%}.|+{(S:qz]4_Kѵo`^tY_4S#* ^zvݾMr+TrkQ g.8Ͽ^i>ӈǙvix>$o( ^qt*&t1oJVu-ql5U6jCЉmĻ*"?JT=K'O/|=Vo}l0b}}f?X[?/\JSBe,kP8ETJ==?.p5ފgbU9}ǶdNKk—_$8̸͓ۍ8Di\BԿ-1v{FF]|.^ۅ{vl12׏z7-R7wE?\nh\jN/Kձr_oBw"N QMBZqe-m:ӨSn6j4%!hQ;sv'm4kcM=!8\m[M4{SMliۇ%eֽR&N:{2A8)THLK3Zj[jPBx#BگMf:G1\`edcʮ?|w(-̮vXt,bW2;.ιNHRR#YwTM"<;mk\.foIDjmlJ;vxy7o7i\,KQŊ9d^Mmgc L*.T6tLeIuOH3SJQ3=F/ʿ<9\JM6mN6=<{xkP!F1QR[I$6ُimXu2An2yԒMU q f[IB-'䤯jYm52&JG\zд\~vdg QtHGXw&1Lw+nDEdC1w|YJmvP)HZ>i0BPβә?R:QO["]I_Jʏۍ>QKyu^bycBq4lXF~l [\*N>-J6,Gq(Zr5h]CwYӤU~ʶߑ u*SIv%ZfJ7)! FS*s_\|IŸZ)J ]ܜi4"z[+Z,MOZ))}|Ʀ(RUNIII.S'ˍO~˨rn}M)xxӕ0 eyҵ7YMAB]ӣU:/ѭ*6bcwP͵ "+qēVjŹO|GtY4V j[mLV M -m>",B$ GD1~j6O4|LxnNmqATNR3ε|DŽa[fmn-ڭ+FiK7Pcm;r5 l8r{#-]'nrFh2ruycb;pW=njRqRJ(d mnpckNnʹ+6]tz~E=ʕ l ZZ5jSi3#47.Lcfe`9؏v囜.F\-UZ:*0_<Νu9Lӵm&)_3\^ҹ3"1n1v_|uRʞͫr'iȧN_kH׺8xXrj=\МH)V\ˬ.Xʸ oVRC}ySU9/OBY먌5 ٿwޞ)rw8Ӫi5*5ZΗcGƱ !ZۄlmpjJ -l <R̵/JAպZuq\IdUS 48wXJJtcg4cI~aqߓwŷrm-v)G7yS^7H^-\mŌAq|"m9IBnF㏉9[N+mmy/!KKۉ%n +BdddfFF6FQRN-U5;Sv'm4kcM=Mn)\qιqUd9F%",6MGdT%-+~ f%+y֛^3SrF>6lc(֪vۊN;g._0Sѧ]ETWرkQKzGe9ʨsKA"yC y2\[5 rԭ7Gk5Mzw_4sM3hxЊ'oÍ5jsub )ͪ~tR2H]R͍>̋m6=%(˿(Wrr-܅y5(ܔJ޺YunW̹븹NsqK ]/QR#"ZMDfD|43Qw|._ԡSqTZBg??O Ϥ)/E_U|i}2 9Z?¹0:x'3,whǣ?C y-A~=daJј&M?D1_PS+Oi&;a @;Dž7[ zZC"bv:jjMQk$M RԸ3uA\=wI.AwC"^.{?-\NSiˏ"b}T/}q/ o.1M}R%:-ZniʒL$SgrBW*,Mw'N\ɇ{s\j]VryG'8f`}'N<*/`U숻z CwHq18J+vԕKss4R53/&XTt1bZƟo\=%nO)h$rBi-nKĪ^ ջڜlwkYm[̑+/QrZo%TQ;TLs($2C:s.%+eoNttq۰kK7O0m_t_pZ1SsSM7"mevFZ[w -FJ*T*jФQRg BSu|]g:ɵzjqwmltL.e3sRMچkSmjkmWœިm++¦'tILk*բQ D,PB\lI[9{%Gb R6öۍmX-MaʉA931cs..G4CujQտ[9 }G-xwl)IQz j Ó"rqe&=]꾧֎c)<kӳ+0JrRR3'TnXi^xMF Bު*tIL.[h"2"nKzZe'ZV/RrNYz]8죝n]Ķܩ>^Ժ]u-7^\mZjܣ9+Rmn ߑv?oꋘ?&ƪy^N4o=3-ؔ̿*`}V݁ ƒPu8%$ ݗ]wt;\y\>='OjPIp/nJU8{϶FNMsf"ίNqƹ(+ ݮF2Km |jܴZs%zf*eȫ?]4)I۵nR&FX + [jDh(#哑9q9Eծj8noǕZf\J-l&Z˫}`ӎhyrΉn\űn]9pʌӣ"׮Wt?N4_I_~54#/my1Xr*척aS#DT >q ssΛW;3oUaJSRMDgQnt:Ql,/ ܷfRqiM Ȼ>Cob;A>ڦWقM9X~/!'MW.}Vrߔꔵ!5|iB(0-zF=}okڢE$^wW~nokY߮\6՜̌{i-AF*9)\t9IV6۸5ZUF6R$ŨQIq砳YUZ]eyv >hI櫥N )&l JulwE1GDOuFN2| }馥uC1rޫV+^gdb&W[4<^e4YW,d|htͮsUM)۸8:{3d{AѢ)~ \#J=NdƮꮓ90 |1K$v*?мS ]i$J,C,SG?/_՜pMSƯM|mG1V1$~K>CSvkuj=&) -,yLjuFHK{c駗.SOua;BrSqj-ۍZ#'Jys7[g2z/.u4+XV2VQ.ޕ)$"(%)#Z7suZ%j }BǬݕe)Jvz8zJf:hIN|svO1O#IEcۍjݽ:SdὮvu^@:o^5cs>i/VqmVm]ؔܢn6'vޑ̗J4Wn@OlKbX ;n:hgJ9ŻyǑz8f܌q&Y fN0N;[69 rbׅC2/#kE l&2~èMR.*%g=Ft.%؝e8<.e=Uv{~㻏"EˑnvDѭ͜Lu3u0:U֝$[M5<:oi+V4V9 6nXvx&_ q Qqw3W:uϔ2yb/(ɳ|5zQiJ#r|Hw#.W?4aDŲ\ugWG;Cw鐢K|xg)##=O.dF˟jMUvWĻsr.z]kPc9"]R)mkfOd*uYf١RsB Aîh=k]ʳUrrZsq`d#r$/Ը3o^&lRWȍyuW̦Y4QDUMJ65ƒ[+ygk XK_±k#y:8(TJOSQhJt2.DR}"5[) r)6V6u5k:eXZmv𭤔!푊Q[qQ}ҹLE- 8qIZG|UM4j}Mܕ[Vwm{} Naqµ"ԈM zOpKѰ?IAD3Ir0'/q1itoB5{%wkOBn-ۜduqIzYK60{+DʕܞqIt";r1mG/\/ym[6JƫR \L=S=OT@Ix[TMm{>ݾտ֒ݸӉLYIx>+"JVNzx||5rI?C{oz8۹e\R-^\A2F R+N9 vlT]"ۭ d)t֞i #E2jB@׵=#/N+!ĕhx}I!cM`ąZ*ŻɄҒ߮Y.Z}='/oۙ3IpW̮hT7cTSuz9>B}΄&h!>lӵn~j˅IvU.'v'CSZw8QK3G> ,J59ٷ+HSg䧎hJdzvwv-cvxS5[̊n~ؿ%ַX?O0\6ne 6kn9.ϯ} *h 8_QhLݣ7q +=XBҲ5?[[)+F`=4 }B,sNg==u*Nj9k_GJ)+R~GSPBȒZ:(K]heL=vKPӢwq(NrG^ثϣ?#tC?.ͼ[ۅo؞y#%ǛjVyLSw%T*s92JTM%"YkQО.q)gCͲn8cgi6j1MѾ[{9h^vƘǚםidfi.^RHmg&rׇz:}݃}xT$ضk'5s-狶,\vpbPD،=Okf.c#cdz2FK5T!&)|ntD<+OŹU i-G[EE*FDfeaf2QƤM\UG_{ǹm%\yrGy:.\4wjPGUJޕUV7Do\7Vy_13w;[?c]H\$IJ,*L]3b%L{y.JRKG2sq,B6T}(#nW|km+q5] r㪍bJ@y{byz,b踊3ϻJ,'^xd،)JVw#.Vټc''ÝպWtbRؒJz۠8!o9IۄS95E9ؔ-e9JR{dmnッ<[~n${~Њ$W?&ՐY_? #a.ߑv?oꋘ?&ơ|y^N4o=3t=~7!/M3>n8W홎2M`Qx+ z qy8%]7_~540ۦ彷]Wq CѡwkďyF5Dum_}~P(5.(X,K9vᯐ?leB9;Jhm#3{CxGE-S{;@Fz˙]=O'!ɿ]' r`:7'2bЖ>Iy,/eTy/V<.H?UYY{\^#ѣr9^7?xoRȆ7EoS_&??zϾM?(~Q-K&>"~aߨ t7Emsϛ+?;fCr)fY+>z$tIkjn_>vnrֳki-˹l= t;'EyC¥|/BLwBJdgjۛ$s S1|ɍV%JI6KvəhzIlBYɒ|0"Sy0F>eo5W)O+X˻u';v)2vVq۳kۮws?UʑBǴYO漪e2MIjPAک\b1)DDؚKm6ZWΨgȕ۶yjڳ 2ضN[C[|r@9Jfo<_eI7q.|cÊV߷:i.:$ȋ)1%%)ADZCEBxJ0MJۥy(bNsKM9k43IwNt.\%N簤I'.j|ƃ2$grBEٌ\}9:v*!n7M(ɽ]7c@XxƱԨ37īf62cTTfFK]9wntQHͮvٱI/f|j=7}\_V5U^+:uljSȃY(XI.ȱmo1甅jڎIZ2>#\*:gY|4k\8ZwSqtyA!+];бޞKծË¥e)#5ap.QK^8VdU{*ѽL\=qmjnB5>{ Ӟ`v±5 ^k&O~Oshɷ,;6nOW>u6{RqS`)S%jp\ipdEBLfTWy$GIYw~䲭J.1vSY5z.V>^+Ǎvc.I[R{QsNR3ӎfhd>y?UJ*}~[e\i5U^͛E]G_FS(Iɿ]i8:4zj~շsW,ˆsy:%O}iur]iF5~3M:Ӟ#N06)4ߧgdawIotiz:1r5YDZLHBSi;NQc44la=Y kQIT*ըl:tq2(է9VO4뒳܂~2rq'nrVZŦ[t7\oլfb/mlpc.I8콚q^1iE~䰳mi[dۧw֤ICfdFeCsg:i| 6擣׋* 96lust^{%99UNRvaMܽo ammi$em4D6DD\nA%$$#}۷/ݕr99JMն[oT޲E"KTaP+HGkŴj5TM5xƱOS-k`ۛkٝWz;{kS}F;~q|~^_|euwnE'pSupUP)V]vE+t =ZRaVdG6= *.ϼnj9:UɷbېmF_tޫgHjVS'śǕًdkkѻ_]Kv?nT>)^e=Ar1'3ԔILyD?:-^in):{7.؂\.:V }#뺾.3r̸*xbFM aȵz 6SQ:ײj[ 8nn iFMw rR"5M5I旘35f^j='j:nNW.ʭocZvZKV^ɚJ.cM1ZI7E'6rg탸5oZ=[m Z`\hbMUR١Ȗĉ):Jin!_7Dй+f̷eKҷvͨBPR(V`y6tw*MRΝcB.ڭTnc;P$8nFvm4(D(R#R-L -2:FP lxZKQc6I("Km%$E, 78uXIFA$RQI$JbInG]c[ֹ:ZM+n^')JmJMJRu{e)7jQDw~%yQl}BZujSSf۩QZ+Dzhd5o%BIc'GZ?}΍:>Ɵivז-%݌J5MqGWTVʦh݇ܟ~Օ_6 n'{3~mϬj'J11OȻn߃r Qr\3y٘+WӍ'WxEs^O3 o~[|7>]]H9݇ZomT@]?5B:Z߂'`V_+/MSKX߆ޠk3?o7y:4R/7þ] iG߬aBRU&?r&/} cQߥGj2?C5Yśe7hU=?+ x龳f-܈czW^7p%-(\D4h{UK&ӡn^m]Fݢ:`δvj俜F+) y[{{ 7 tu>gvrěOj'5 iRg[ͶFjGe n~qT$ci ۚ0oԹc*jL[sVWqj\ݻ&6"WoK:cnWmrv)o>66(F>=W^bf#c zzʞtپy%mՉPël e}J.\Zk4ttt>oEM=q)hJjI=ͥ(%]脼_88ф;͛gWG;Cw~˘$4=uWdĜTثNDkiQL9U*O"4XP`02,Ge-k5$h>ܼ]3vr6!9RQPIVSnM(ۓ{>;/Qͱv{3&-[rc)ܚI$n{Sv3[j00)-D3z}MRzVQпj,T[uVs0\}Sid;r(ݝJ>æʺL&c[jPK0~d(FKÝW\m]GTcF|Iׁ)I3~#oX%vҦEݑؼ5Żv2qAZTE^..M{ʐfȏ2##.R}*KʛZz^ӞN*lPťLf\G6[WVQquV]XAi)5J!,$iJ6o$tPZc;Kjx_n3`qIelV~vLy{fn匋Ѿn%;zV.n'-ұdd2߽1bZksPe3TI9)$ԩIN9Vơ\=2885N\ p)/a柛w9g_lױo8ݷ iixJV& ғRi{N^_oAŮE6Y7I$Nk$|Q)-*4Z)^¸%4Qm [I%.c-OV+C֧R#%ѨCe3i;w$G+_dy| Fzj$DI(=OA gj%v/]8qԯNIS*֩',Q%\44ZZ%D|Ǧʴ6&vֵI$%8(ԬƾS&#Z. }6z?b/|Jl{ץv&mpx4Z$”ڝ4-H%dGKfM:sKSRWeJAn]>s6应-W9'H]'uȫYvgK^\czp|My\鏩w/ËQ.)]\QiS`8uL뚛̸=J"ܻi\å'-)54Ue]:K\퓡vK xwBqrH\*֕TnzC.mT=t-H]SČ~Nu╏NÅ3f|͡G~B+Xm[Q7U{9"~jgK Zoʰ7"qJ,ekSeNGgϳ] ^.6:s}_,%eRg<5⿨z{ZPun#jRІ.6g T.!]xa c#jN$Zpl̋H WZu8WmMRýsĮ?Mco~sx TU҆Q :KDG4n42.<3/'^?6/ܠڒ^yrrÿr2\D}}B]^E~^T cɛ7϶Y[<֞[7d}2%QPqOLEQR\CIsj1?\}%tJ0e~ *sk"*)&ۓEi#{1J8Hrt|'ܝRr8)=ƔN'RVz:cf]F7bZyZUȘ4x8,#JG̒?.W9XnO]KO]%]ƻ O5Γ/3qÓj؍/r̺rƵ 5\&m6h.xoeX[=<3%< lZ"2h\Z[&jW3ejm?k&[]ųj+{N{66leu_+lj]q* 7g*knأYv= q ەdxЬZ|%GUrQ3jLŒqET]1% qkXYūYc[7Ś]QY\jko\</Lc7+'hMSUc6qXyؙ~6#ѯv.0$BQi5YyIhɍiy=KD!n3Vm[V%W-B%swa97ajۗ m+9~]fKq|Ddaˑ0A]_v޺mM5* F-BYHJ5}q>ʉ.6hyDmpD׬'-_v5;5[8K[viJ.3dR:oYHHh9I7:۽fi+wm^ [)odPѱ52CZUJicSw\&_s0uBȍh32džzQflcd^m|7GѹE!fO5]]H9݇ZomT@]?5B:Z߂'`V_+/MSKX߆ޠk3?o7y:4R/7þ] iG߬aBRU&?r&/} cQߥGj2?C5Yśe7hU=?+ x龳f-܈czW^7p%5|Y:SJE\U-(a_cƣUǽXXKiȞNlmۊڭڄR!**ܤMeȽ$|X5(Ź\rJ~ܮ]>'HB0cp XFr_c?f?7<ukSgov¥iG>>䙗i.+t+bOjIܶ . i^:nm}s}(3>NZ$2Qg([".>i.ƾ)B̋M8+"- >eE6DݥJnJˣt׻ 5.˅nJGwZD~!i۶a,Db3ZQ3O#KO5/֍ozuK'GbRi᝘NV_ҝcvם ZoX}F6z 7e5_e:ۓj=AB+iܔERadMBq*ԯ DwI/Gy*mĥiRKg6skY/#SN4e$-yXM YL?^ĸNNӪ{$r1JJRSLO]Aqm>V/s[~i/j+m>z}eI"Qvp]{ZԼ:{vPAG2=T͡@ڐ#u"E*>C;o$~C#_d/HBq^YRٽzIKbOm\~żjFFGdiQ(*/i*#.FF]©m=BmpQQQSP&Ҫ!T&^>:y)$ˑÐFčI Bӡ-t!bM WҦŶ'UZ=}zvn~oT/\ǒ'nr8 AJIӆz<^uߖ4eFC1i+v!3qNyߕni?4JZlmYFXFۼO0B\m[ tʄU3s"Sr(NJ;SKW72L4̏BVdf^Ҹj\]ȱ۪(ӷm?J-KEmWڽ^4<8qu%9pŹW~877ܾeVгS(յe^C]yX͹! םm4FGȋ\y'Z FX7e)|Gjt߹#gb\ŧq_([R8[qU$Z (ʻezV2V!iQ,i$JE˂٩ a(GK'O{vnBvryRd-RK4=qxZJMl_CuuIz @Rt㮽޳!|68\-l[џ84-2Pu" RJ_^OL>G1~XnBŬw6J0*Uvlږ1N G1q9IUm*'oWu][&UyYZbBZRZNfEJf"+2nF~Eû7n1xv.RUM$6 lAxSQJ&n5ܞwlEói"#>4׿Q.nEq7Oko[1wg8ZQwZYiqtm&~">Bo?w͡ni2峋NCEy Ҕ+%ZJ ʩq*fpˤl,~^Mχk1+:ݕ z&Y`KLӪУDr3[*Z :(SL&ݻ۬Vqsyԭs x|iI߽zZrg.:mp%6ԜvgmpIUt;QbS.Է) ǨKSV,*lڌ|5Jt3#NP.=+OZ~/G سIgbꥹJnl_DUM\iM!֔wVZuԺ,yV.Q>f v:݇WiaŸN5Ҕ[M7SsrvǣrMW= \8ZW-jsnڕ.ZnF2qt ً[ٻޘY۷Zm"Jxr&NAfA-݌to9s359݆mZ+N1-qS$D=17 x׵+%_ ve4ir6Z$FDڗnFtOr'7'{9C˨ꤡaYoace{Refnft RR"4%ʌm:Sj3)OdInTO>X'vxV#jܮw9Fog;5.~Y5\~18YQܹvj4+~t7S ﬕs %^۵ڴDZV69R^Y+rj$ԇoJKR5wB9C>Y:l+EǎS{ʲ{T6Wi* ^^9k/y/Cs\g*qڵgn4T8mERr|Ti+iPe;;.i\EBEJ 丬i9ɧM-ԼsGDrZ>r#R>~X9y4b棇9JwV۔%m(b[Tjvl}۩~nDԺ{Zo-YuK1vx.nWuO+jN [ٮ0%"΢CdTJK-RަH"$I(*ve &҉FzB,_Vpqp9m8werv')E;o&QE׵^d9˦j\_,ڵugZȻ̧8k+jK{wmr@3ӭ2 wFkzFVqs1؛.v'I%$[iT]D5Dl2 nk7qUxԫLS+sا3/ΖeZYK<["%-g/kRs:f3;*E ت wJ%)5&+&rw*霣i|sMҴ|;R+fm䡩.!**dӶ-6s6,]zAXMWjmnz%SJߴm2UXw7MQ%<!tKys#P,W>s;3IYwx<+i_\\\U6 u7P|xbn_k&ӓVOe䦒 VUr,-㘘"-LZeOSҠթrEvq8Kf%5%&K"#%vD/.ZYYŏ+p$nZkvއuW9㓱Z G wYIFyf)?ƎUm5ԉ/'k84{KO:rQI}XRuԪ|*lu)3qZ[mSm5R3".Xcَ5c®ࢫI*۳~wRϿQWޝ(EJrri&ۥ^ʶ齲Im|[yb;mnm֩uiܘq>E+Ikx߄3r33-5𹻖09ϖ9[Tz~mr5NsWl$oPusޛ^{Z;);sڹf\3oٹZmԉ/'k84{NO:rQIBø8Bݱ3n֤DiK4u& ofSȒܩx<˘|N0Fչ]qsp"}! QWw@t4ӭ+cO5%]'*{eM߲DRO1y*q8w++e!c߶ܪlZWّM欼 CQ̼빶lX{vib/V/ ai;x6~]+z]MWB>re-:lgk}պ!#9?%܋V-c[z!W?c7YNm/jRr[HOzԻefճ0q15Zp#rkQQ0tU-AmڵP/cȕ?0cZYj;:0ZM=D6g ?'UN+ձ[K ܖB2'xq9{|۫N0ku 7xaj;n\ 2[VznMlWiKbSk))f..)Km)&bGZ=>OR܍W:j'rM'wYz&/鶧{Sʵb"vջq[I-ՌZH._x*BagC'T(Q:$ͳQcMCKy?3g'ߝqnT);qs #ؤZ}OOI:cfnc8W~qy.;^pVl]Hԓ>^H^@7-AA܃nmL(uWܻS߿ Td95Bdh4t6*dDh!EhI[iŨ\L.&Nc ܮf^;$R)\rip9I|ٺ?#R.ZDZ;/]nݻqs\QE9M&Bd ]N mN*D>tgbK>+ˏ.!23]BȔR1ɝ^j'k2ƮqBQq[$di]icV/e`޵B.FIIJqbi>Ӥ|p; 6${)RU>_e}^dzdfzi %ekRVUS?6'hׂ)5.\+qUgzE2C˷ecŏ^֔ibk shesFWJ#~> Wk~ݨ}ڶ>ơǚ)׽ZƉo~B-ڼrvoE:Ʃ3ۣK7+Y`WirS):{>ڛ}:wԨ(J_";6R%[u&ƫdZ_\'np| RJwNeTW,=rrbnkڄ[M3ܴz)3- R.?:okۼ0TU'w{6&w7j1z3ON'fGoO?)S_bQ_¿R(^ԴԴG.EtMڇ&RUiW uQjU> Kiu1d<ѥIQ'RQ1:O/lŗᏩiʂv&Jc{D5 Tt)1.n[n۶X}RjqnOʽ(~[Ns{ސ⛌uO,kgo֢dRNQȄ .'6W!׌P朼tdZjFGE"]K@'i۪N;sI[{SOzk>`rRR+!σj8&TjlvA̷Q?HyjyLHNտJMjܶT۽lG?SnKN%<‘ nq[N0Sq[Ta(&t(|HGO~gvkݻTR4&Z$#ViOY1r$6YF?e4U/Mvxų:zbU^gQQ+NW_'4jfz^c'#`rvrڡ(IJ/J ݦ6 ]-CW |_{v*_q3^DZ}Ic6Uڌ8p7{crZq5ki`)mU6|-Z5^iEz3P=:Cu7DF'k%}<C-޹ֲ̱#\,(f88%X-N(ck0VLR~} G"-8ӏ/ϰKq?(#nrVTmZ;zióM4 m |UT'C^_1X.gXM{%ʤd 4\ovN":"y-,T)fLQgۢr=/CƹǨJVr[a+!rT|%Y\ٱzsS>jͱ.oOc6f$q% ǒGo;n[];ߎjrk{~\VۓNIGn:iqxo |~t5)Rxעri{Vi&NUOl_ѮMfsޕkЄay.0P{7N((BaIP$ K"U6Gl ݙqJRu+qN$ m#*p<|{:>-Ev=86N*MM긭U*uѾ?/^o7;'u,h4݌xښRM:5.(/ \իU.{F^rmF-Jɷ.>Q"[4xT^OZ~mK}T0ݛ^SAo9u?lX(' qj%=X}"^e4wˠ|rܫ 6I\Ķ;Ӻw!'ڍWg{ i U_9Avhۣƾ+:vs/MK[ɭīe{`Zgb}r[i'GE2J7Nez579wRq+Un ]J.cJ4M:h箽Wxxm^ pc\wcN%'My $$| :$Fqɏ¾^қP9J6Wxvu}ݵP>Z'FFdg"-; [¢cmWkÎT8nG%ݣ7*\խCLRYZͤiD&J#'ehbSyXK|y*ӞpS̍R`[pTr/Eg)K+92{_ n3zwz'oŸۤ+sOj J:`T>Cf*lwd\fYOP"R E֢̔L4ɥ :;.b(B02rJ蠟9>V'9M%)IqnhP<%,r'P/vNSwr#w"ݨaqc(|{kd=^0jTMR2ULNz|.<|^PfY22##!,K~E BEJۜ&jRNsHަޛg\r,v؜.jK3)[EJ2ii{KEiHP^&]Gn8x=K}Wx/KI9-ϵwQ%spܾ[^R}S3$qvq8M[ ozKxcqmJ/ӿ{_}7&ݨ\f6ZSyQz& 7ۉ[8~UNn|nkiTB+4RI8'Nc%tn{!]Ȋo.nEmʱn𵵥J A+wy#+ikǒڂ;՛s85'KmE:Ђu""Iģ5p=БbTY-ͽڔ詻ngL2Q}$de# fs^o{DUUsfwӶ;s1T,ǤtޒQ\෼J=.tKU,7čJ5 N$y3kdSMQU~mO[03 $zAڟsF5^뜞"Կ QHmrR"ӳηer+ҔZ]hE-6Jmt'ޒ=O[sQj)6K}?e4v_KfZheޓ=BV[bY}lݒTTЬ{ȫvO_qpRApVŗ 6ju=*BR)g "O1yhb=tqJ gtm\b3RY+JQ^Ō֍\յ\>+uSi{=x ^w;uӘ#ĸzLn*$anok߷CBӷ}5Yqvdž<( "_OWit5:EZj2 B ρ1̊fi[n!HQF82q1牙nqnEpT(2RMoM4ϳOu ':֧_Xjsg jP^(ڙ{2%E͖j^}ZU[Q$'U) <܂%!s"m R'G5M0<+zM6qYm$ڕ$3ǧH]?o2N<8F1̻r_my[Rf59NjpzBnl7*{.QP 3N&^BLJPjAHCK2Q}$#~YMq8 k(MFMU)8MEqTy+Tʞ-ar5yܕOXw!e;q-Jqܶ䓊Y:LC UE{/t>r"lI9)3KJjϤA 6SEE$d߇3KG*En|P\ԭTn6I-ƍKTj<1H_zwGr19wF N8ݝ+a9ɫM6mhePi%mmD! """"""*1bRKrD"vnrM۫mmĽm]ӡiG~e"˩ lhRTMk^MX["Jݱk7_ޕ*DqĒ&flՒ}`W}~SմZ{ĕ~wm*/{{ѹ_-0ط#P]xlڱ~Tn5wi*lڪ (JxioϏbqKYR|!|KN53 OS222$jzww%i}>N)E+rۥ7c$Ofl/LNث\6H9: FY󡈾I)fB֔JI_ ֣^: 9mY{66㒢7Uj]:.-os[R&gMF3˸#໹kmjq^8W"PΦURjʄWa˧T!͋ lW48JB2ko+ /Nw QwQzQ ے%$ޓ7^YL|r7!v%Trܥ &|M8~ybrn[RV gSn{{*#2#ԽᢏӴHak" ӌcwҜw&RJ07ױ>Ļ =^ BɆ)v32.M1=#6%̠tҤnzqMwԣ~s*%-j|_m*.Yx9Sz=)qE4 3pk+,`=kNRڥ=B=nŔNAx)Q$ԩȧ4z3t#Z2lҮYn$S%y- JzGpu|LBV7ZW#;Wwipܷ%(6jFG5#{$D"uۭ~]֫SrD܃fҎӾ+Tu>-ZTQ& N|$沸ii>eRWݳu'[O̻j8JۻEѩ[]vni= ڒ,[_%kC7I3Nv$4ɎЈeٸoUu:[}Do5|zNq=Tre%ɧ6&~DȍF]ƞG5q m]/w/ \ʲr8=oʔe9U(W"|S]uZd#?Se[W"ֿh][-7Nu:T=)R}.;ml*5Dlf $fF(̏T hiIUU4Szɕ t(%_|2 ~6eM;TƗK[f&]LK^CE2[ȏBOd;Mi|cx,^6;sیGpQ\NuJIFTJ~đArh* B"$H쉩eXPRj?sl"ԥ)su]xpԴY%VESH"ЋJǰ K&5^Ukzׄ8kEgS2h&Se\ Yl]WҶp-ZUvi7QS:4byqOo+[̺腋[6-_Fo.6[7$p&^ _GZԸߍkc.qqoI[9m߸YxOZЦ1uoiSH)P9Uʄjcq= S>֙NeR><;+ڌk%_qT].srNO?s[=vH[]RZHRMtᩗVؾ:/~u)ԍdg%=edVrISb{6vSu=(ܥ)mTv/J}̇8 S3ad:^hBSf؉OɔLhI_1d8,L><_A0y3rXq"'(۱;mFNII.v5_(^q~X>y{3צ I*Vܛv/jW' T'NR'j%ꔩ:mJ3SB}΋!-H-RJBТQoedi9tjENenPpke.%4]#{:>mkEɱdYWl\\\'nRM4&U>?Ќˉk÷!𴪛]]5}UqG~ݏI"O~s6(Ļ)qO~h}uԕd}Q~G,oE!&G&/]_H-O=o{k\̭bkv.Ô܈+;arZx)m?M\3lU$mk-CFXjTv6u' g:Vn_*qk:VC A%'4JV%EY)#BғO4<e׿jQQ]yUr4=wm[K1r׵%Iũ-O}|kC;/VcݩWZ)EHdžTru]8hgĵ-;=>U_ InvTm_jBM+QiF"9*{DI/iuo(=TzϖmPQl_v4z>T*ȴ>YF;ε\t]EH4ꌇ[VrLzef 2T^V>g2~kg5~Nק;{~Z~W}&ŒBӿS2$J?~(Yœ"˲ߩ\O]: J׉ښT{mmIѩn3˧)4LdFZ/zUG>U> n 5& ϴ-KJi2o]uKljvK3$bԔҚV旧iY5.ίfi96v7!v))FJM4{jG~Jt/lUE%pTAFe4qQk\ve۽/u/Im+W')v{\-E|Pms7߮DZRr۞/mu*1ՙaB܆ -xg3#6ۥtRogʌU)׎]ZҞNnŞr}F1Nnޞ;cZ{N}ۿMiuxʉ*3qi'9KHQ$WJxXyرŔe~[v5~/jN9Q4o6rJv FrdxM*iRjMzUinHdн7ᾞS=S'7 } ̽zt7K|_g J=Lq+/Bw_\ۧx\HJUPzQ<hqF[V0x==CsU7q|^ {)Iq38$_A(VgcKu06Ƅ"%i~_ˉk QCܣB8Ku/񋇵u([w}$F|8TՠI.E !;RJ^}MɒD_q2];Ɖ{5}*n7nEInO{Mwv}&q+v [V}Ĝ@%>#dXQ$f;iep.GquixVt x6bj͵mlKقQ[T]zs/&yەnM'W}!Fp_d^Tu N{ɻ'l{խ2.sTu{W^H&;1s)Pӛ6>$mě;Łnj= fLT)>׸+qReɴ[UR\L*P/!$Ӊ3Q 'K=m~6XqW3^W+ųO_[F$rR*u"T%@O +%# ]˽!aܽz{ͷvQh쩎]hGތ5ɇ*DzJDRNLi 4:{~2FmXY-zzĽ^f=]uū{/+&c:Ma{ĝDp2m܍kHș/(--m_vݮK(V{R}.k&yƴ7i^4@3f sK3^Ř˸B=]?gt5KbZB<e;kQLpxuWC}n 5ҴepB##~q= `x]KWF {GfŲ}?G.I9pjWkU]>={7q{kO/^I3==f1ɏ%nnʫ/Zu_yXN<57ۍ'vy/"8넭M2eԷ&Y,в33%IkjMr7xf nmQkX4踼>a-GcIeތw&U=-:qnW)z¥j :WqSZvԒ#j"KrIU)%qrmRoDGQ~SYRsu*V)  ,/x)MFD6O#]z 96[Ui(JRfw'y$GeUީkdMF-ݻ98F2d[o{Rn0n-xsV6Dh|Eb2E:KCOӪv4SJCr"J!!m,hRLD| ZYFm/X~ΧfrN&4Ƒ=Z9Mh.Mܵw/BdrܥniŪ8ɧ|y%œ[M=_tj?F!z5\evM:\ ~F-sg钬OWq“iiȍ<Gi%%n2rqͻllƑ)okw7}\Uk-:&fj솘XerV9yZuʼşdFC=rmo%~ZN78X(N)_7.Εn1MpJ}62jjJdI";R5&iLԸc:jmqiQj$ujp\{;v5B񥍪Xn Ą4qOERjzN(Ga٠䌡)p*v(J7#ZۻZ8O W uONb+^Qipv9GvֽƼϯrYƖKGJQDNPhRJjᡧC"21"9ѓS1;R_O7/WGz)8fE%F2ukmvSov/iZ&/]~KmI[:^~ͤ\kMi稜\ywJt3W7 8Ʒ~ݥeFgѼw"8VVSج\뻆}ݭ/J6Q)d|)zU3>k\L=;ow֯gN3pKѫ|wmkZ$z^2R:E)f>ς нd|#׆?\ǔpV{;\$ƵE%-ͪm0S6[n< kE[}mvE4DDZ^$OZ0*$~XUv҅B@^?]so#%ojw;Y#SxxueBگy v^i-)s)zV jC{7Gt.w3v,ygg8s]aE_,*E tY5k٨h=o"m泏:\6w噓aiL׎n^c\75AGkЯ0Lf46َ`egZ˓p/k;̛]kq!ݸzpԭG"}R9Ve>ˏHUjJ-&7nrnwG*Xv\˱/vN}O)ʼn&CV͍f̵]r\PMB-6Du-#RͰtRN^)mT _}nSȕC*_xBuTkJW[`ɩ`ejvsngP ڻ.-WUtܑqԹQj)t;vN&RNũT+8%IXӃ5fK՛-d9 ]CƑm|nZ-6=Hz,*aEm W3VzRšdY~Xf׀Xx"]s;)5u*ُHB BRGS6bݶؿ 9j[1*jױga7oX CUI%0v#~\-O-Ꙛuɷ쏪&5mY٦M`LJ2qK~HZbr =N'YobI. (^ ׾{_ ?OJ`S`3BN[}5w6:ǵ/iSlt=4F*d&T4y/#. ɵim5Uֲf 眕6Y7 fơ=3dϕq뚩$qTM-%r!$@A? ޾V0c~{[{;򥧅a~ڵ»&ڄv1ek=wb MLkNAԬw-x>~/r=e73VeVN)K%Sښe"+3uXuچrn ֺVzscJ峻m}vb㶓n\YbIUBT%*,0nov=;z꣓S/nSXSpl##k9mXGrZv^Gde!ŷRԠzQyjC]`gToPov{j~KRBMY}i[߶9KL2ԉO0K#m>wB[ٍ+n[[b٦DX ݲpo] [\m5qdT()mo4Oy9Ie b][wղmM~vmi۱~t \}$яimRk(L c Cvk7r9_r1 ;zv|F@KyZ[&jEji/"6$69ml#e]9s\{ScL}Ȣؿ0q/nZ*t,CLoD߉Njǚy=Pgmu6^]l-["çUʖMlʍp-"qmU>۷uFOJ%Ǔkx 'g=睋k[3u,{³WɘݪF]ՍeFX"Oy\,cچ=w/gn Ļ]#2? vqy-gXnR.^}ݺFs{ŝG]}e|#0mjx"ƬWكm?rgU^xVB":Dt>@LRbun~ݭ,w+v⪕;\U(RYa61>#Jm˞Μ9g9XKaG='u8gf}'qy#ɉw J]We.ʲ-<+&q%s?2dњztҼn`cΤmmqMdz O[-ߩӲ&;[tmܝVnr">{x<8U+p:Ig]zjGkt,uzf}dؠoJaکqEq -(:d<պ=eKy[˗^%ZXkX[C2߱\ITTLGzANM￵i]K>UsOGDDD.ZF6* ҃V Zhz{'xp^`wo8r0h ZmJ5"jb[l=yUu7-;7IT%:jFjߖm0tzU'K)څNۧYJ)4IQ}^KWm7kSP>q;ނ#)'n7&׊r?óM{IwR\j2Qn[v pe#/tAF\ϵ225q֒om6z})6҅*oqDsMf CNIN=T S2t,_ѧ}kveMF0J\Rnnݙܹy[rUc-j{yGtkQ%s]5qB.Nw.JN1LvR Ui5J ZESQԙr):MJ+g}χ!2;q([jAud][ljVK3$ײSJI=/|&tl'*n۽f.frܥ jQO8>&Z];.|7T/C}$ڋUmP2Reҭ8hFF\L 3~e v\۫]ݝNmrnB%*]Z«hKc=BTLG :V74$=Ǘy+EX'4tn(I:Ѝ;Df8c,k1%dJ6.j6ź{N~l6&*fœI7 WAlGOu-ҢH,,(ǔe뿋쩨kM܍ZſgRvQ' 9)?n|er˭|I|-fGK.rΛp8XV1%K6mvG+tc+qE&ǸC_Nm:l=_/m5^[dߌڇ.c<%:)tQ$Ow~-aY;UJ>=F)2[nk؆?훐M=l6[4(O.]2#-H^n#->&mp5~Fӛ+|| S,xag%qkEUzUgæBhߕP(7]kFnq?֖CpruZ6*rEڊtS|*tI*E}7R<,nUU֫^I7Q*mSly%rdȓd8hE<9oHhMfNSRj[i7D[Rj݊+kდq{"$$H?p\̅S?㭻;t~R߁)^/>Qj`yt[w ԛ;²~+ߔ_ YW~|o]?x^ᯛ `ʼn;g)T@vWn]>&4lp+$D̢1l|ȨF%-}.9[}w~ ԠLM9hСablfe&QoW!s?wjLK?s7yO>(=C~_nyǜu?v3vyo oI@qV-jeES^[9WoSܝh"l2C1a͔CiJ@3:Pճw=/7ovuk+\V;lDgն<[A+rX~d;m!_s8ݖ׷;;.0llUC+?i#_crʙ1~C.\–q ul8Hܶ2m`ܻM3Tov|Bs rɵ"oLS- DКw=Tv@f'6|YlD͓Y%׵-#Ѯo%:&!3o%\J<02;K87>^vgƓ# ;ݝmz^Y6=PS39U%~ &f# }o!muH;ʲŇ˷yvP+&.7e[3'vR4Yj̗IZ`e˽3o[WU{ m[sUbۋZǾۆl6~9'V*.\S2<Sd*zY[aŶ`]C$n.v^Ʌ dng>ەZ,Mmϑ :n6nϦezWqUJ4! ۇ4R! =>>Fn|Q[{pRO17ƕ~._I''00k=b՛o}Osðc2'o\3}ݭQ^2 . R1yKȣtAݿ-uܾw!`?1Whn|gzUo[ECWwjUIן)^h#1ɭ!/Z np;o;ΗŻkXs."6E`Z1 עӐ9Kl8qd q} 2Stt;#j>;խabONŗ=fwP1j)l6J̶|gV2`y/0E˛6+ԫ1? 6}KW c\KoKͨ2ۅFw–s*TԞLיuDx .kCzWXhy۶gLu|%TnupǺl-S* PRaLnT+c+*xl.v!.U=|; !_L̎뱚U=4hm:ٯ"y)$:>%(n}X'p[ȴ ^˒4kƓmzDx \ 'NqamP7nyN݅=j7%McSڵj%STy qXymvCg{w/w=wSW5r̹u erծˊsOm=DhEҚRb#n)QOxtվQwe]I}wCa'"[ۂ-z}2UuKP$㜉ԧ:mc<Ý>RoL?wu|%ҷ&K y_!y9 ??:tq3(UU-lkS'ɸ@jdzQˬR] EVPW1DJq2n:,c|ǻ̑;y{X,ۂ.u.b˕u.tKBjQ"[S園S`ٮdNبeJ&9Ơ ~0a(Vm٘L+Jr*vڑE( x0+tp˕ n';wm-ޜMOxX>{#2%jgb2M[`K*\5@8l'e=0u+w ֘鳾{y܀:R*Ya]"Ӧ%ktynlۣ65,3gU}{GYrb;ge'TKwǘ.,rpܚV]Tr,!dp /ԺU,xՉ>s׽~W5oTh yx?xrrx?)?ilbT׬,z$Ԏ.UH٠\U1pU:]JwSrGZq8àd驐,N67QYBӢD㏙W!Q25ϸo9ms-7-%3CihO.J鯽-;MZM8ku-7k9S$8]q2E(}bۏI[DKOK}3KUB^u %Y,u.-&f#]'܆o$x`Yu,dzwM;#oKxn;\[d7}Rb+*Y䛂ZuBӱl{j0O̓}LhK;[aֶaGL{Cb#S.T[>߃F]NK"u^LUʐ_ykW?!GRj29͖qa'0[npcDvV)qz9R)PۨM^aJx W] r>];eN3vxdmĘ(5W2K1䪖weF{mE/QP6\u54x5[hۮ-Nk”i[lUgL]J}5 S:EhiUrgHl!ŒJ$pe=q^b͵Q' ?6|R\,JA ڵ"TDꈭ:ymg`B5t%M] <N_zv2_Ortٵ/i/ReӮ*7[qүqEG* m"[I:6e^p"I$jԴęh!m)]GZkcjS!{e^z}+Cѥ9;R|/ֱeiUԏCNu2Zhcٗg$ݭwvr P8*7/Lk~I'Km1+MW%Bk|oOm>-#qj*|Dbѱkn|n{v#jĮqNpMIUm(7Liz;{ҜݞڝVƚVϬ+sO!OstGvxӉ']uӎ4g_ 1^-8ۦ k!)Ύ5O;YSB#2Zzχ;<.ֵOtge~.(RC#wFZeGZٸ6FFJ4e2ˇpJT$[wgV)q6muDGJ56q\I!̗ y/I~RtJ9kJ]Iy*'FN0s.[l!fw'y(7$œ WƫgyΙdMEU JQJv̋vmrۖ.jWR_M֨djYgSj0^\y'EoECjm$ IƩK>Z28J2TiJ2N#}.s cArl嫶nB.FIJ.)۔\ZiM>/hLĸ=C1s[?YMqp|94- 鮝𦔽/k^#NT(Y LS$6˩}{;5 )B۷W$qpN)qqoot}ZDVә;7TiK|6f3h$dԄ}fqݡ>Nb򗉉+ͶO]>ߡ_VtYf79ڰիF sq~prս|QM)g%l0ocJȨHz V;Bb/kLAcfPJ,ԭ{ƍgpjNR6VSI*$!yV足jᇑ.](EܣqM\qJ2eZT).<9UB/(B0j)mtKEj#׿fDI-=rZړj|'Nڤ]k*i$5qt"ݙPM6E4ke^Z8ۏhz$Q(R Ay2zfRñnpnkbkI:=j &ΝșW?׵d{+ύM'??XqeeĽ.[o=UxFS=ӷdZwenՄ]_X=ĭVa* pKs0ބۍfJ3 gz̚i|wnxtjc¼5${(1fXQ65ȼb̶Zkn>%FQMJXӡ{TZEVNᖣimT/37cNJUPnP҂ZOE~"-Rc4^b- FEͧtf5[)S!OZIښݲ͑;tvܡ+N)AR=hCNn;wL16-:特7M$=Tҕ-.R[HٷnXk sn[ҞD-0WS9p9:-Ϸ-jѬNu{ҹfv)[Ľvwfg(ٷfe+0mYj8Q1\ݧg]Eǎvڿc!4#j5̋C2"}BRriFp7=ô\TZ:\BLfj#I22װ<;صZl j 6:l"6]۸ K'6RTѯ^ئOԓV\?$x7s#r:Oh{ց=MmuHԷd{pN /܅:UE#Yy+(SgQ(Щ)RHzw>^Ѿݻ>mK&^ '$Jۻ&w%F|xfz%˳ L~3N?Cy9 v w/{ƿ kz3x> sXv}vP"@WyC z`'톽Dw%-tt yVY\wmuPYQA0iG-2JP,6/gˢ]u.-n!Zw.N7Q]Df}Q0({a\@=i_X7gFǘ8^⻲}G MZ1)WEfO12G+=-B@z\`||w6ċj߬m}UwRox֢I &c~XGP6Qndpvܻul'V7^FJt^{b^B(L~sѣ6@߿^xqU!ڙ5|Vpvef-uӥ^3  FSDɯKD%0r}FF穛r7 +o"V8tv̖NQU!5uFd"bCr^bJ=֤fM#ʳԷP0O-9xRBm\=`r-:;~3Tl(nXtXi%2Vٛ#vwqƴ`L@"H‹qW.j,JM5B[)WܺUeZFqc'V˷1W7V̾-MHФwn8N;HPSdݷC7&2j.W\τGŎ'Vb]c.x+Rx1%C2T{myg[qU|+m:M:շ8҉yWd)ՋWS%%:iqlʹmGwݹ WnNŤѩ5(9hTٵDdGUi-)vSs2 2{OnT$Xck n:¶(lASLeȔBjμPpTb2~N2~%^k[ܗ[Jzs0ӓHBKq[}JَA-$dFQgjxxFv4r/x*Rm% `4J(&iv7SkԲmSH1YWmx 8n.k']:Z˭_W >ڃXЩ. jTq%Aā[E}amc]D:rmHRiu:uӚӢ\p(5-q%e)(۬ҖȽIf<߽pr&ݫVfY91q2ĭEQgYbTGQ&,yL+N$[q*RVۉQ=FuTܻ>f>f㋳8N6$܌n)9&»iˤsX,݅܍ȩv+sRTpO}d?Wn/Inpȸ%O]StQO|v5\}7Zwb.AIVK^:wb{[uݯcytO߶S<{8KSRׁH̏N7ۚ[xkwYy_'ZӵF+>쌛ZUĦreE9F[24De{}@:ExWs-\ǻ7K-\JNvEk%:s˙#κ].oͳ;լ7wB6nwu:$L; DkI#Wz.:Xp(˅v$Sq,wn\qIN-e<5Oe+vuYTpcojUI_ާP8 O 7&VL8z$_B-H-[uh]T{|8=qVRN-:Ij:7PUtXϷmy鉿:RIM~33ӸS2#׳GdŲ5+/Bx{(WzȨ5Y㞎#|˖+ ط.|e<o/rߔX>7s}VE.OVti׽ .5nNJO"95{#q}Ay9do]R"M6z\tnNS-D!@3N_jicWsy*5uٮRcWv/.,j}=S)j5C^> Ie =gu9ӛqjtz]۪TMoߧI!Ǧ¶m:,"[L!{qAv-o 3{"KʼnrIkfٶj2ƙ؄S`7` k6jzޞ?e5G&6uʷ2%ԒRKE*G\Npom F/V |C0.q_eenƣ<5Oh'67ɪn[SĽ{ڔjǘzs;~׌(ۂ`ܢ1ƣ` _l9Va6%UQWh~P~\F^ZHR@:ۧCJ{ôGeBh;~ۧnU J\O+n2 RҠ)ng}Kh{5+S×ܛ.1ZjG)iRȤIN 4%{oΜ/eO[Nffd ĹK?nnԼMqX'܌nZvq<ķbFnͪaQ`5 s,M_լ?-@_{w{ӺձJ}GF[%v\5[ŒGkOw/ΜM9rjË%2+rd~+󲕛C9U۳r[aJǭm|˒LAʨSCq[XMۺoubfp:t+ΤĻo ][ zt-*67kvS7D·MMCQXm;)܎n_h%]4ܙnRk!]ڵsDUF"`R, &#R_*[z*ZqFXɻ]7|۵w+'pFDەs=r./ᐚm3Hשy yD"jHCr':sA65نѮ^o1V/ f;nFr3VM)e*- s D'H݅fӧ\*޷[k<7u<-]֍Q8R h|p=WlW3s%Q %3l}@U-K6f-NϿu|ڴmWN׮[׸F*mW\%r! C78:޳vBG7ŵ.JթԚ2x)ST!řn~9 W:Wpܢ件{xf8ٳwKE ҰWxVB\qBZ 2wMb[lGSnyԚ~z9ZmያvoN2Afnݽjf>)j3 !;gOYʹK" Wftڎ+׭b*2ϻK>ۢӱeyԪXISUm[z+ugX%0lϏnvg!;t{BqPj>PyvR7Cj]O%+ݲ :qiMj6W}3vC/R=4Som]ŗ=ю, TF6U_-\6MyskwMr&Q\wjKܩyMϣUj0*}RZܷSdY3>Zjqj6TgzpA/M`/Cmл,޻feE[/+uk^Vs1W$G(JsW2ٰu*߻q*Y޵.Wi:ur5T),=0uRmho.twܖiYwrWHntvEj8qhf`Ͻpf(R&>Ki%I7$QӖm-2 ~yߗQ-앑/ x[k8nw.c㩵k}]FkbJl:{.(˩n0Hqvαp7 귎.Gupx[N`Yq'+ruU7[ү+>!xrȫoSo]OC# d^Q]\>!ƛGw^Mx"-+%vdX-:M2UR%d>%l ioSu6lsj7D P>XxHz Ukà(n^Q V>5cVtWj SEiJdznyej[lE' 3kuٌNn4JW)gB {4 j6&]' m-(ZMEz8cz>WZ6#7+[,MR-Z!4ܓtCyE|umj1ƽvƷV\;%>Q :#Le(iVz5 4ũۤUWxX ^(ҔsլB2w-V ^R+; ˂M\z+Uwr+RWY⺧~ Q*JcYSNSλUd8in=v K낫k\IRרSUaCFmϿ5̗P|u ZTԕ}>oYѲ1sfP+sQkX8Gb~6r,s>^\,mGL+7[n-E\.Fqḕcl*Jmjb5 ,m]c}NXfeVlǸJ5eˡ$4%g~N p4Y*WwW٧<8v#;qԩTut,m"#Y D\5V`\\Lȋ];LȇiS6ϝZ l>LruR\v=ǘϔDg=ԈdFZ+M{=|,[;0>RiSi4,S5}yxw&(E7&fݙ4UՕ! ~'Id)]ǽu2K-fޭ \08Vڅ쓬=Vy^^ IhyKR-B#Ըr=]mܻӾ'*Umkoy rTqT_i,/8Q^<ݤ|4ԻO(܄"'5N~#m.(Ҿ2i6Uev&I*<}҄$eNtÛzyWJubW^iBW.܅Wڮg]irO6Ve90sgv.+sV޿aޔ[p?3q*FutUo*eL\KM'EG*ZcAFfG5J 5jj=MJ3OK:k˝'NMB7m3uFҕ\-Ywg%PRqMIyZGY9|μvn߻5cWݷa^+X֥vnݘ\v7m>Fgzv"-;Ew֝}1|RjN𿊀7g#֟*GQQ|#/bo]p$>_Un9гUbn9׃ErQBU-^vDmVh'<R[fdHT]*~}3j;nvjc7s-rӳ Y8[n[1pJx kX[Jk9Mn!_Nю6x:iZ˦U |߉^Ԛ݃hYxk &U^bwKk.[jE+P(˞=9j@snCv7%c_7=xǁ<l {t'酚+1F‹l׭:ݻILruǶkL-L(K0L1&>wXB(pm;1fpnlp֓%Skidkt(U +xulo'/ڕeN r=^pZZ:Pnj8Hf"48ijY[ N[yZٻ+=  ø:3 ?^ܷ^Sr#YK[UF?CuhC b]GM')mڏsNrܗI]ljq6VB. W,UK"YX5{c >Iqā> T:n!,5l2VzCl|+I[*SrjnS6٨y+x,@>П.g+!rn9>N|W>OZT_ut Y""v7|sfި;Pclm EùN,{'fNT%U&LfH8~1v>Il}统u6P˗c(WV~H^bMU.o*oOF0N:_:6Smr_.b+|ݶYY غF,mwjv>f*>QM뭱Sd:`N{l/⎱;n-z~"Gze퇎J5S KG9!Gn;N1 ݎ h6m|S?ɂ5'WOÞ 7|7^ao @mxGmi^jϽ>01Mf0լD3-2T. VXR"ɥV Kl J O7|u?bvа;6.eߓ|[1bmRr,eRz`z 6܎-ͨku͹Fː dPhYgZUj}nvX;z=gVեTv_J }\1n7w2J?ޘγc\E 1Aޑzq;\r]]\Y&[nsNei\uURje*Qk2CSl*xJz-xٶlm+|UjUؓ`Ladqiĩ!Gd\W~fz;Tn*PdRM&T4`չSWq5k훶(N"Ӎ% V]֦wb.nUO!u*J&Oӕ2e|Z=eV쫚΅g#+/RW:طnbi*Wyo)p{:ETKؚR(RY+r웓r(IF) VmȵNB:h Q1ғ|u8E]{,'$-TR[j49l*3"I鯴zhd>Q+\BkNF=.$ZR4Nwհ(IpNi.(Gi33#33e$FXK*NdWrud[r{xnk$v2ıh+J1TQ[#JQl[tRO]LHKٮ NӍnF񨔤֞Em'MILB"ԋ%dBŋ+p̿_17jzT~4pc Vo\ƹb9Rq-'1j;8ܗ)hE%DZKS<璸Bu*%*Yw5ڻ9ۣ^z4U; Ñk\U(o~G?VUĎ:?P?_F_Kߤ~ᓾI |pr.Ok\SklRhҪz{­P .}SktZ7UQ4ڌIM8̈eaӊJZ%FFZu,KZvln廐SNFIVtuNi?CM5]+Ph,{jN JSR$IS^tSUVrORYu.9WyP6 [Kiu m!X|]Y79ӄ)\ģ)pbڳr%*&ꑶ_-H*dzk)1 V3')UAϹٶWRxe'պn۫h7AR9 EAJeGLms!%D| A 5]/Q3eb̄vnVn%za\m kZnv([emqrIҕij|""><hjJשvvǕ|Pޟs}V~2&Z?+2N&Z4w@)4iSڪ_>/JN9Hiۏuf8'It[ȲR.hZ$ȋ_Y ~U<UUO*6b)Ovzڜj\R̋.$FsQuҊj^נ䈈y<zZIuP[}Qm=C?zN(Exqu/kn S-FzKZzOסӽjJ\)F3b!r5ٝ|;6 o=-3*λ]αb\abqRi-w޵⦪~b8Kpo)Z=>)ғ"5/GTZLE-輵f7ݘ۹~+&+w/7GFI:l33fg.N~۲\2|*cnermnnM+Fq"ѪIz%j =YW8@~gc/~?N'?)«qȸs➟n=k" X“m֮VreMh2[uݖ] *FܖN)MȐ`f0 g,C9̑o;ddudJ=In13:ݒvvdMUEJLp^,6t-@͐9'{7m{-3,>hnF;ѰM)->>+Ěz!R* :`e--m7nB\u{b U>[8֪]6^ߤLʦ\DFNo$$dͶlgno8OrsQ\l̯hRo8tuNo+ CTxu!2[>ctFpeޓƻֶR"3QrQuOѳgwQr;S~)6HhZw/GgVTmUf_yt7%$];zLWF̰xy2Ʉu!MCmš_0[W6jf#a-KLi+3Q7c^qg%s<1aYIQeZf+}>;S6L0]Yu_h9߻<ƅpmiM$AVvŚ,*#t2.8Y)-Zhshü97/#Oro"u^/uFgWɺ,p:6a,^x%$Yve^3PƗMnTP&yS}OJ '덫MH^:rXԴJۋ/rI;S*,+yz1hv)Qw^ڍJ2oL׊q(\fDj:^T%vOadɂnS}ZO)N*λdaȜkG_PIEO}нa(^iQX᯦-7^)%g'SJx(.S9zVɴZ{E ))ۅi/s7 VIV-|sj0*UBTHIqRf>FP$KqN0 R̻8j\GcC}IUz\i 6F)Q{Gҧ3qSzKj-Az VЛS-zy:8*mNk|D鿓ND2u+0Yŝ7kqm·?8Ib]u>˗^_>(]vӋzv+ݩ){vZrJ2RQ몋C$z [,pp,8mڊbR]Il .f~d/ݓs㓓mͶ{mgjQwn=Oic9ܚm4Q/6ݨ[TƧ?nԶoytf{@AzT{e{[O'ZRZt~AGD?s3􌿂ՉIw'|~U\ w~di:Kޱ)U/sU%njѩ&GSP^ǝd)..!^U` 1wX[aԇSxoFV6_扐)T 2Mfd=ۖͭiZ7KK Bi9%7@<3<ճԻU,},a}FRqɛr i@ONJvK KLN M, ʖv0n-]DwlI-X6ܶ$Jʴh5O+mOI+Ra瞠\ MG7BفjYo1#͖0V`Ѱ2M?c8>-Crt*JkIGS:e#hPKx[鱼>{5m;wcն&>j-M֥^َ) 6yȜl_w{-ō̱r> U=]iw3)r*]:K]6BdCTZ|>gf}LW}[$'Y5 &c -j.z6R 67MԷFMnÌwI7w5E}o޽+K ֵy4܌ȥW"COyR[q5Ӱ͙f[v"_#q{MV6܍3"u9BK(41ӯqˇc${ߝCi6I(OmθzҜ5k^:>Jzw.>qV8{vU[ڶEm|DžBz].KHjI]x;Mɗ{m,qZXr忇2u^RO2Z}ZێS[2Jen!*NDcrBUً4<ǼMҲs1Zw57c3&ĖڻzmP*FuJG1-dN:|OU}ҵgi2t~F^^Z.VxjvŧnNNh<:]^~NN+ge^g.SԔGFe߯'[vn'(ScJ]kܗ7eJOlRrfziݮq̋S"\*U<*W]k$FջV}? 7g#֟*GQQ|#/bo]p$>_Un9;l S VvQU%OLU{οmU6bZ1MTx%!֙Q7, J=!3 ;Q,ڌ;6ͱ݅q^&ߔ·n #WbwӖX.HtG)N&d̵zpI,n cu ޖUj+VXUp[w]N o.J6Z8Ts&utxln;~HPHS/xw`G\ʡ¿rj Z^vt"[L:SD\h0sUwR,}[x^X,R2Vn< ]2YDr[SRKs8tXb̷G?Ps Tv 3be,zVz D[/I.KOEQrm'$7|[J>r S`5յwT#\w1FTz\Ԛ &"ׅhSHrD\'r]~/>p;:Piuu:"9ő=tTaS7V2rӷk7mb[^WmPp*[y.Þ6f]cizJCgRR@UVl큝.WJP1N{/\whZ ػϧӱE7|E֫Sί.x-Y&pi%v''-x6r'Ws*6=DwwUu]=C?MK [yrtܒG$!WGqJ*%SAz ED[^)/tė/g=#Omd.|^n/sl׉g DZqemqowݮRzUܜ=ڽ-o/Iۖ;qVʘgPp|mm;6zGl9.8pwWgsJ2qPbe}}UpNjٯ}7TMQKrؽtEx%v w߾8%|j;~|}pK]ơ/ w߾8%|j;~|}pK]ơ/ w&~e_H 8PL7:%ʭ5Kw&U2vwR_+rm'}C7#rWoO&HoG?M$UR7{FU]u ;# !Wk`|W>׹潇9Vn)6)*ҹ{%qV4q>W1vi#T"Qk&GwxcJBJ- Ϸ^ˁxkU}ԣ/3.;]J=<*)cS)ROK9H=,r zX @)cS)Da^ԽQ gxJI=w֣gf*TRj

Correspondence to: Woong Bin Kim, https://orcid.org/0000-0002-7369-490X' target='_blank'>orcid , Department of Urology, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon 14584, Korea, Tel: +82-32-621-6827, Fax: +82-32-621-5018, E-mail: woongbins@schmc.ac.kr">woongbins@schmc.ac.kr
• Received: August 8, 2020   • Revised: October 15, 2020   • Accepted: November 30, 2020

Copyright © 2020, Korean Association of Urogenital Tract Infection and Inflammation. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 3,444 Views
  • 22 Download
prev next
  • Purpose
    Acute pyelonephritis in older patients can lead to a poorer treatment response and prognosis. The objective of this study was to classify older female patients with acute pyelonephritis according to age and compare their clinical characteristics and antibiotic susceptibility.
  • Materials and Methods
    In this retrospective study, 360 patients aged 65 years or older and hospitalized for acute pyelonephritis in a single tertiary medical facility from 2012 to 2016 were selected as research subjects. The patients were divided into three groups according to their age. Their clinical symptoms, blood tests and urinalysis, underlying diseases, causative organisms for urinary tract infections (UTIs), and antibiotic susceptibility were compared.
  • Results
    One hundred and seventy-six patients aged 69.9±2.7 years, 142 patients aged 79.4±3.1 years, and 42 patients aged 87.3±3.1 years were assigned into the young-old, old-old, and oldest-old groups, respectively. The duration of hospitalization and fever due to acute pyelonephritis increased with age. On the other hand, the maximum body temperature was similar among the three groups. In blood tests, erythrocyte sedimentation rate and C-reactive protein increased with age. Among the underlying diseases, the incidence of diabetes and chronic renal disease was similar among the three groups, while cerebrovascular diseases, heart failure, and urinary stones were associated with aging. Older patients were more likely to have UTIs over the past year. Older groups showed a more significant decrease in sensitivity to carbapenems, amikacin, and ciprofloxacin.
  • Conclusions
    Choosing appropriate antibiotics, considering the patientʼs age, is important when treating acute pyelonephritis.
Acute pyelonephritis (APN) is a highly prevalent disease that is most likely to require hospitalization due to various symptoms, including fever [1]. Approximately half of all women will experience at least one episode of urinary tract infections (UTIs) during their lifetime, including APN. Moreover, one in four of them experience recurrent infections [2]. In the United States, approximately 250,000 patients visit offices, and 200,000 are hospitalized each year [3]. The annual incidence is 15-17 per 10,000 people, with a higher incidence in women than men (~80%) [4]. In South Korea, the annual incidence is 35.7-39.1 cases per 10,000 people [5,6].
The symptoms of APN are diverse, including mild abdominal pain, urinary symptoms, fever, and life-threa-tening sepsis. A poor prognosis for patients with APN is associated with old age, immunosuppression, health-care-related infections, obstructive uropathy, reduced platelet counts and serum albumin levels, elevated levels of C-reactive protein (CRP), and bacteremia [7-10]. Among these prognostic factors, particularly old age, the population is aging rapidly worldwide. In 2004, the population of those aged 65 or more was 461 million, which is estimated to increase to 1.5 billion by 2050. The Republic of Korea also showed a sharp increase in the population aged 65 or over (from 7.2% in 2000 to 11% in 2010). This growth rate will continue to rise to 21.4% by 2026 and 46.5% by 2067. Because of this tendency, age is a very important factor when treating APN patients.
APN is treated with the appropriate antibiotics for the causative organisms. In Korea, reported antibiotic resistance rates of trimethoprim/sulfamethoxazole (SXT), fluoro-quinolones (FQs), third-generation cephalosporins (3rd CEPs), and carbapenems (imipenem and meropenem) were 27.8%, 21.8%, 9.3%, and 0.4%, respectively, during 2010-2012 [11]. Therefore, it is important to consider the patientʼs age, underlying disease, and clinical characteristics to select the appropriate antibiotics and prevent antibiotic resistance. This study examined the clinical characteristics of APN in older patients, as well as the differences in clinical features, causative organisms for UTIs, and susceptibility to antibiotics according to age.
In this retrospective study, 360 patients aged 65 years or older who were hospitalized for APN in a single tertiary medical facility from 2012 to 2016 were selected as research subjects. The patientsʼ data were recorded in a retrospective database that had been approved by Soonchunhyang University Bucheon Hospital Institutional Review Board (approval no. SCHBC 2020-05-035). Informed consent was waived because of the study design. APN was diagnosed when it met the following criteria: 1) the body temperature of a patient was above 38°C, or the patient had a chill; 2) the patient complained of flank pain or tenderness in the costovertebral angle on a physical examination; and 3) the result of urine culture test was positive and the patient had urinary symptom (two or more of the following features: dysuria, frequent urination, urgency, and suprapubic pain). Elderly patients aged 65 years or over were classified into three age groups according to the classification criteria of the World Health Organization (WHO): young-old (between 65 and 74), old-old (between 75 and 84), and oldest-old (85 or over). The duration of hospital stay, duration of fever, and maximum body temperature of the patients were investigated based on the clinical records. The results of the laboratory tests of blood and urine were also analyzed. The data of comorbidities, prior history of UTIs, and history of previous urological intervention were obtained from their medical records and compared by age.
To collect urine for the urine culture test, the area around the external urethral orifice was cleaned using boric acid and normal saline. The midstream urine was collected in a sterile plastic cup with a lid. A 0.001 ml sample of urine was inoculated into a blood agar and MacConkey agar plate. Each inoculated plate was incubated at 37°C for 18-24 hours, and the number of bacteria grown on each medium per ml of urine was calculated. When more than 105 colonies were cultured per ml of isolated and bacteria were identified, they were regarded as the causative organisms of the UTI.
The categorical variables were compared using a Pearson chi-square test, while the continuous variables were assessed with one-way analysis of variance. IBM SPSS Statistics version 20.0 (IBM Co., Armonk, NY, USA) was used for all statistical analysis. A p-value <0.05 was considered significant.
1. Clinical Features
Of the 360 patients, 176 patients aged 65 to 74 (mean age: 69.9±2.7 years), 142 patients aged 75 to 84 (mean age: 79.4±3.1 years), and 42 patients aged 85 or over (mean age: 87.3±3.1 years) were assigned to the young-old, old-old, and oldest-old groups, respectively. The period of hospitalization due to APN was 7.0±1.7 days in the young-old group, 7.8±2.6 days in the old-old group, and 12.6±2.9 days in the oldest-old group. The maximum body temperature was similar in the three groups. In the blood tests and urinalysis, the erythrocyte sedimentation rate (ESR) and CRP level differed significantly by age. On the other hand, there was no significant difference in the leukocyte count or hematuria status among the groups.
Among the underlying diseases, cerebrovascular disease, heart failure, and urinary stones were significantly higher in the older age group. On the other hand, the incidences of diabetes, renal failure, chronic liver disease, chronic lung disease, malignant tumor, neurogenic bladder, and catheter use were similar in the three groups. For UTIs over the past year, there were 10 cases (5.7%) in the young-old group, 23 cases (16.2%) in the old-old group, and 14 cases (33.3%) in the oldest-old group. The history of urologic intervention or surgery over the past year was similar in the three groups (Table 1).
2. Causative Organisms
Gram-negative bacteria were cultured in 327 (90.8%) cases, while Gram-positive bacteria were cultured in 33 (9.2%) cases. Among the Gram-negative bacteria, Esche-richia coli was the most commonly detected causative organism, which was observed in 213 (59.2%) of the 360 cases. Forty-five (12.5%) cases of Klebsiella, 17 (4.7%) cases of Proteus, 15 (4.2%) cases of Pseudomonas, 15 (4.2%) cases of Enterobacter, 12 (3.3%) cases of Serratia, and 10 (2.8%) cases of Citrobacter were encountered. Among the Gram-positive bacteria, there were 13 (3.6%) cases of Staphylococcus, 11 (3.1%) cases of Streptococcus, and 9 (2.5%) cases of Enterococcus. E. coli was found in 64.2%, 57.8%, and 42.9% of the young-old group, old-old group, and oldest-old group, respectively, showing a lower incidence with increasing age. On the other hand, the cultured incidence of Proteus (4.6% vs. 3.5% vs. 9.5%), Pseudomonas (3.4% vs. 4.2% vs. 7.1%), and Enterobacter (2.8% vs. 4.2% vs. 9.5%) were significantly higher in the older groups (Table 2).
3. Antibiotic Susceptibility
Among the strains obtained from urine culture, the antibiotic susceptibility test using Gram-negative strains revealed 97.2% and 97.6% of them to show high susceptibility to ertapenem and imipenem (carbapenem antibiotics), respectively; 71.9%, 67.3%, and 64.8% of them showed relatively high susceptibility to amikacin, ciprofloxacin, and gentamicin, respectively. Although 60.9% and 67.6% of them showed susceptibility to the 3rd CEP family antibiotics, cefotaxime and ceftazidime, respectively, the susceptibilities to cefepime and cefazolin were only 48.6% and 41.6%, respectively. Furthermore, 59.6%, 50.5%, 43.1%, and 19.6% of them showed susceptibility to trimethoprim/SXT, piperacillin/tazobactam, amoxicillin/clavulanic acid, and ampicillin, respectively (Table 3). Regarding the suscep-tibility of E. coli to antimicrobial compounds, the suscep-tibility to ertapenem and imipenem was the highest (98.1%), followed by the susceptibility to amikacin at 74.6%, ciprofloxacin at 70%, gentamicin and ceftazidime at 69%, and trimethoprim/SXT at 65.3%. Less than 50% of them showed antimicrobial sensitivity to ampicillin, amoxi-cillin/clavulanic acid, piperacillin/tazobactam, cefepime, cefazolin, and cefoxitin. The results of antimicrobial susceptibility to other Gram-negative bacteria were similar to those for E. coli. On the other hand, the resistance to carbapenem was higher in Pseudomonas than that in other Gram-negative strains. The susceptibility to ertapenem and imipenem were 73.3% and 80%, respectively.
The antibiotic susceptibility for E. coli (cultured in the largest number from patients) was assessed according to the age group. The antibiotics to which patients showed increa-sing resistance with increasing age included pipera-cillin/tazobactam (57.5% vs. 41.5% vs. 38.9%), imipenem (99.1% vs. 97.6% vs. 94.4%), ciprofloxacin (72.6% vs. 67.1% vs. 66.7%), ertapenem (99.1% vs. 97.6% vs. 94.4%), amikacin (80.5% vs. 68.3% vs. 66.7%), and trimethoprim/SXT (79.6% vs. 51.2% vs. 38.9%). Of these, cefoxitin and trimeth-oprim/SXT showed significant differences according to the age group. For other Gram-negative bacteria, the susceptibility to antibiotics was similar in the three groups (Table 4).
UTIs are among the most frequent diseases in the urinary system and can occur regardless of gender and age. On the other hand, women have been reported to have a 4-10 times higher prevalence of UTI than men due to anatomical differences in the urinary tract. Approximately 40-50% of adult women experience UTIs once in their lifetime, and the incidence of UTIs increases with age [12].
Old age is an important risk factor that requires hospitalization in APN patients, and it is one of the common causes of elderly deaths in hospital [13]. According to the 2009 census conducted by the National Statistical Office, 10.7% of the total population of the Republic of Korea were aged 65 or over. This is expected to reach 20.8% of the total population by 2026. The Republic of Korea has already entered an aging society, and is advancing rapidly to an aging society. This means that the national healthcare expenditure is rising sharply. According to data released by the National Health Insurance Corporation in 2014, the number of patients diagnosed with pyelonephritis in the 60s or older was 42,817, accounting for 28.4% of the total 150,611. Of 100,000 people in the relevant age group, the number of patients diagnosed with pyelonephritis was 592, 583, 624, 732, 792, 992, and 1,050 in those in their 20s, 30s, 40s, 50s, 60s, 70s, and 80s or older, respectively. Hence, the incidence (per 100,000) increases with age. Therefore, it is very important to investigate the clinical features, causative organisms, and antibiotic susceptibility of APN in older patients.
Lactobacillus is a normal bacterial strain present in the female genital organ, and has a competitive relationship with pathogens. This means that conventional normal bacteria, combined with the hostʼs receptors, can interfere with the attachment of pathogens and compete for survival with pathogens to obtain the limited nutrients provided by the environment. When a woman reaches menopause, vaginal atrophy, and symptoms of genital dryness can occur due to a decrease in estrogen. A sudden change in the genital environment can reduce the normal flora and promote UTIs. In addition to physical weakness, older female patients after menopause are presumed to have simpler cystitis and more progressed pyelonephritis.
As a result of this study, in older patients diagnosed and hospitalized with APN, the hospitalization period was 7.0±1.7 days, 7.8±2.6 days, and 12.6±2.9 days in the young-old, old-old group, and oldest-old group, respec-tively. The period of fever also increased significantly with age. In general, normalization of the body temperature is a determining factor of the recovery prospects and the time of discharge of patients with APN. Therefore, older patients have longer fever periods and longer periods of hospita-lization. The longer period of fever with the older age is believed to be due to complex causes such as a lowering of the basal metabolism and immunity with increasing age, accompanying chronic diseases, complications, malnu-trition, mental disorders (such as depression or sleep disorders), and secondary accidents, such as falls.
The ESR and CRP, as possible indicators for the severity of diseases, were also significantly higher in the older age group. Hence, the severity of APN increases with age. In the treatment of elderly pyelonephritis patients, the possibility of progression to severe disease is higher than in younger pyelonephritis patients. Therefore, more active follow-up, including additional urinalysis and urine culture tests, will be required after discharge.
The risk factors for APN include diabetes mellitus, urinary stone, congenital abnormality, pregnancy, and renal transplantation. According to Min [14], diabetes mellitus was the most common cause of APN (17.7%), followed by urinary stone (6.9%), congenital anomaly (2.2%), and pregnancy (1.6%). In this study, 31.4% of patients aged 65 or over had diabetes mellitus and a high accompanying morbidity rate. On the other hand, there was no increase in the accompanying morbidity rate with age. Diabetes and diabetic complications may lead to a shorter life expectancy. Therefore, the possibility of survival bias for patients aged 85 or over with less accompanying diseases than usual should be considered. The incidence of accompanying morbidity rate of cerebrovascular disease or heart failure increases with age. On the other hand, the higher incidence of accompanying morbidity of these chronic diseases is due to aging rather than APN.
The major causative organisms of UTI are Enterobac-teriaceae. Among them, E. coli is the most common uropathogen. Recently, however, the incidence of E. coli has decreased while the incidence of other Gram-negative bacteria, such as Pseudomonas, Proteus, and Klebsiella, and Gram-positive bacteria, has increased [15,16]. In this study, E. coli was the most common causative organism. According to recent studies, the incidence of E. coli was 87.7% among causative pathogens for UTIs [17]. On the other hand, in this study that targeted older patients, the incidence of E. coli was 59.2%. Further classification of the patients by age showed that the incidence of E. coli as causative pathogen decreased with age: 64.2% in the patient group aged from 65 to 74; 57.8% in the patient group aged from 75 to 84; and 42.9% in the patient group aged 85 or over. This was attributed to the increased frequency of opportunistic infections of other bacteria, such as Gram-positive bacteria because elderly patients have relatively lower immunity and have more comorbidities than the other age groups. This difference in the distribution of causative organisms by age as well as the increasing incidence of non-E. coli pathogens in older patients should be considered in the early selection of antibiotics to treat APN in older patients.
An examination of antibiotic susceptibility showed that the resistance to most antibiotics of older patients exceeded 20%. Most causative pathogens were highly susceptible to ertapenem and imipenem in the carbapenem class. On the other hand, carbapenem should not be used as the primary antibiotics in all older pyelonephritic patients. FQ or broad-spectrum CEP should be administered as the primary antibiotics and adjusted according to the antibiotic susceptibility test. Because the severity of symptoms and the rate of antibiotic resistance are higher in older patients than in general patients, carbapenem should be used first in older patients who are likely to have sepsis or septic shock. In addition, resistance to FQ increased with age, but there was no significant difference. The resistance rate in the whole population was also increasing. Therefore, the use of FQ in elderly patients with risk factors should be limited.
In previous studies, the susceptibility of E. coli to trimethoprim/SXT was as low as 60.6%, making it an unlikely choice for a primary antibiotic [17]. In this study, the susceptibility to E. coli was 65.3%, similar to the results of previous research. The resistance of non-E. coli was approximately 50-80% in most cases. Therefore, it should not be used as an empirical antibiotic in elderly patients with APN.
The patients were divided into three groups: young-old (65-74), old-old (75-84), and oldest-old group (>85). All patients were initially administered empirical antibiotics according to the current guidelines, which were then changed as necessary according to the results of the blood culture and urine culture tests considering the antibiotic susceptibility. In short, the empirical antibiotic strategy is to use 3rd CEPs and FQs as the first-line. Nevertheless, the use of FQs should be limited because the resistance rate increases with age. In addition, carbapenems are highly susceptible, but considering antibiotic resistance, their primary use should be considered only in high-risk older patients or patients with a high possibility of sepsis or septic shock. Furthermore, regarding trimethoprim/SXT and cefoxitin, the resistance rate increased rapidly with age, so their primary usage should be avoided in patients over 85 years old.
This study had several limitations. First, the number of patients was small, and the number of patients in each group was different. In addition, this study was retrospective in nature. Because data were organized based on the medical records, some of the history and patient symptoms might have been missing. Moreover, most patients were older patients living in specific urban areas. Hence, only patients admitted to tertiary general hospitals were selected, making it difficult for this research to represent general community-acquired UTIs. Older people living in urban areas and older people living in rural areas are more likely to show differences due to higher accessibility to antibiotics of the former. In addition, patients referred to tertiary medical institutions were likely to have undergone primary care already. For that reason, it is expected that they might show exaggerated resistance rates. Therefore, a more precise investigation will be needed in the future through nationwide studies involving several institutions. Finally, because the study was proceeded by classifying patient age into groups, an evaluation of the severity of each patient was not included. All patients, from patients with simple APN to patients with obstructive APN who require urological intervention as an emergency, were included as subjects if they met the diagnostic criteria. Therefore, more studies will be needed to classify patients into more clear diagnostic criteria.
Even in acute disease, long-term hospitalization can result in a high medical cost for a patient. In addition, it may increase the incidence of complications by raising the risk of hospital-acquired infections [18]. Therefore, it is important to understand different features of APN in older patients compared to younger patients, anticipate risk factors for long-term hospitalization, and try to select the appropriate antibiotics.
This study was supported by the Soonchunhyang University Research Fund.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTIONS

J.K.Y. participated in data collection, performed the statistical analysis and wrote the manuscript. S.W.L., K.W.L., J.M.K. and Y.H.K. participated in the study design. W.B.K. participated in the study design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Table 1
Clinical characteristics and laboratory findings of elderly women with acute pyelonephritis
Characteristic Young-old (65-74) Old-old (75-84) Oldest-old (>85) p-value
Number 176 142 42
Age (y) 69.9±2.7 79.4±3.1 87.3±3.1 <0.05a)
Clinical progress
Days of hospitalization 7.0±1.7 7.8±2.6 12.6±2.9 <0.05a)
Duration of fever 3.2±1.0 3.8±0.8 5.1±1.6 <0.05a)
Peak fever (°C) 39.0±1.2 39.3±0.9 39.0±0.6 0.061a)
Laboratory findings
White blood cell 16,811.4±4,888.4 17,833.5±5,516.8 17,775.5±6,066.0 0.196a)
ESR 97.1±20.3 107.0±25.2 109.7±30.5 <0.05a)
C-reactive protein 11.6±4.7 13.3±5.0 15.7±5.2 <0.05a)
Urine RBC 119 (67.6) 92 (64.8) 26 (61.9) 0.739b)
Comorbidity
Diabetes mellitus 48 (27.3) 51 (35.9) 14 (33.3) 0.245b)
Cerebrovascular disorder 25 (14.2) 35 (24.6) 12 (28.6) <0.05b)
Congestive heart failure 15 (8.5) 25 (17.6) 14 (33.3) <0.05lb)
Chronic kidney disease 13 (7.4) 21 (14.8) 3 (7.1) 0.075b)
Chronic liver disease 10 (5.7) 17 (12.0) 4 (9.5) 0.135b)
Chronic lung disease 25 (14.2) 32 (22.5) 5 (11.9) 0.092b)
Malignancy 19 (10.8) 12 (8.5) 2 (4.8) 0.443b)
Neurogenic bladder 32 (18.2) 19 (13.4) 5 (11.9) 0.394b)
Stone disease 25 (14.2) 34 (23.9) 13 (31.0) <0.05b)
Catheter indwelling 17 (9.7) 17 (12.0) 6 (14.3) 0.634b)
Past history (within one year)
Recent urinary tract infection 10 (5.7) 23 (16.2) 14 (33.3) <0.05b)
Recent urologic manipulation 10 (5.7) 8 (5.6) 2 (4.8) 0.972b)
Presence of cUTI factors 98 (55.7) 86 (60.6) 25 (59.5) 0.667b)

Values are presented as number only, mean±standard deviation or number (%).

ESR: erythrocyte sedimentation rate, RBC: red blood cell, cUTI: complicated urinary tract infection.

a)Analysis of variance. b)Pearson chi-square test.

Table 2
Distribution of uropathogens by age
Organism Total Young-old (65-74) Old-old (75-84) Oldest-old (>85)
Gram-negative
Escherichia coli 213 (59.2) 113 (64.2) 82 (57.8) 18 (42.9)
Klebsiella 45 (12.5) 23 (13.1) 17 (12.0) 5 (11.9)
Proteus 17 (4.7) 8 (4.6) 5 (3.5) 4 (9.5)
Pseudomonas 15 (4.2) 6 (3.4) 6 (4.2) 3 (7.1)
Enterobacter 15 (4.2) 5 (2.8) 6 (4.2) 4 (9.5)
Serratia 12 (3.3) 5 (2.8) 6 (4.2) 1 (2.4)
Citrobacter 10 (2.8) 4 (2.3) 4 (2.8) 2 (4.8)
Gram-positive
Staphylococcus 13 (3.6) 5 (2.8) 6 (4.2) 2 (4.8)
Streptococcus 11 (3.1) 4 (2.3) 5 (3.5) 2 (4.8)
Enterococcus 9 (2.5) 3 (1.7) 5 (3.5) 1 (2.4)

Values are presented as number (%).

Table 3
Antimicrobial susceptibility of uropathogens from elderly women with acute pyelonephritis
Antimicrobial Susceptibility p-value

Young-old (65-74) Old-old (75-84) Oldest-old (>85)
Ampicillin 57/174 (32.8) 40/138 (29.0) 11/42 (26.2) 0.626
Cefepime 119/175 (68.0) 88/136 (64.7) 23/36 (63.9) 0.789
Cefotaxime 123/176 (69.9) 92/142 (64.8) 29/42 (69.0) 0.615
Ceftazidime 127/176 (72.2) 102/140 (72.9) 28/40 (70.0) 0.939
Gentamicin 119/168 (70.8) 107/142 (75.4) 31/42 (73.8) 0.666
Cefazolin 119/174 (68.4) 79/141 (56.0) 21/39 (53.8) <0.05
Ertapenem 169/170 (99.4) 135/142 (95.1) 37/39 (94.9) <0.05
Piperacillin/tazobactam 156/173 (90.2) 119/139 (85.6) 30/37 (81.1) 0.229
Amoxicillin/clavulanic acid 111/176 (63.1) 86/135 (63.7) 24/39 (61.5) 0.969
Amikacin 167/172 (97.1) 131/143 (91.6) 33/39 (84.6) <0.05
Cefoxitin 153/176 (86.9) 106/142 (74.6) 28/40 (70.0) <0.05
Ciprofloxacin 120/176 (68.2) 82/141 (58.2) 20/42 (47.6) <0.05
Imipenem 172/176 (97.7) 131/142 (92.3) 38/42 (90.5) <0.05
Trimethoprim/sulfamethoxazole 107/176 (60.8) 89/141 (63.1) 26/42 (61.9) 0.914

Values are presented as number (%).

Table 4
Antimicrobial susceptibility according to age/uropathogens
Organism Antibiotics susceptibility (%)

AMP AC PT CP CT CTZ CZ CX GM CF EP IP AK TS
Escherichia coli
Young-old 18.6 53.1 57.5 46.0 61.9 75.2 28.3 58.4 65.5 72.6 99.1 99.1 80.5 79.6
Old-old 22.0 24.4 41.5 50.0 64.6 58.5 45.1 22.0 73.2 67.1 97.6 97.6 68.3 51.2
Oldest-old 22.2 33.3 38.9 33.3 55.6 77.8 44.4 16.7 72.2 66.7 94.4 94.4 66.7 38.9
Total 20.2 40.4 49.8 46.5 62.4 69.0 36.2 40.8 69.0 70.0 98.1 98.1 74.6 65.3
Klebsiella
Young-old 8.7 47.8 60.9 65.2 56.5 52.2 69.6 56.5 56.5 65.2 100 100 73.9 65.2
Old-old 11.8 70.6 76.5 70.6 64.7 58.8 58.8 41.2 47.1 70.6 100 100 70.6 41.2
Oldest-old 20.0 20.0 40.0 40.0 60.0 80.0 40.0 20.0 40.0 80.0 80.0 100 60.0 20.0
Total 11.1 53.3 64.4 64.4 60.0 57.8 62.2 46.7 51.1 68.9 97.8 100 71.1 51.1
Proteus
Young-old 50.0 12.5 62.5 37.5 87.5 87.5 37.5 62.5 87.5 75.0 100 100 87.5 75.0
Old-old 40.0 40.0 40.0 60.0 80.0 60.0 20.0 60.0 80.0 60.0 100 100 60.0 60.0
Oldest-old 50.0 25.0 25.0 25.0 50.0 75.0 75.0 25.0 75.0 50.0 100 100 50.0 75.0
Total 47.1 23.5 47.1 41.2 76.5 76.5 41.2 52.9 82.4 64.7 100 100 70.6 70.6
Pseudomonas
Young-old 0 66.7 50.0 66.7 16.7 66.7 16.7 16.7 33.3 33.3 66.7 83.3 50.0 16.7
Old-old 0 33.3 16.7 33.3 33.3 83.3 16.7 33.3 16.7 50.0 83.3 83.3 66.7 16.7
Oldest-old 33.3 33.3 0 0 33.3 33.3 0 66.7 33.3 33.3 66.7 66.7 33.3 0
Total 6.7 46.7 26.7 40.0 26.7 66.7 13.3 33.3 26.7 40.0 73.3 80.0 53.3 13.3
Enterobacter
Young-old 20.0 80.0 60.0 60.0 80.0 80.0 80.0 60.0 80.0 80.0 100 100 80.0 60.0
Old-old 16.7 50.0 33.3 66.7 66.7 83.3 83.3 33.3 83.3 83.3 100 100 66.7 83.3
Oldest-old 25.0 75.0 50.0 25.0 50.0 75.0 25.0 50.0 50.0 75.0 100 100 50.0 25.0
Total 20.0 66.7 46.7 53.3 66.7 80.0 66.7 46.7 73.3 80.0 100 100 66.7 60.0
Citrobacter
Young-old 25.0 75.0 75.0 25.0 50.0 50.0 75.0 50.0 75.0 50.0 100 100 75.0 75.0
Old-old 0 25.0 50.0 75.0 50.0 75.0 25.0 50.0 75.0 75.0 100 100 75.0 50.0
Oldest-old 50.0 50.0 50.0 50.0 50.0 50.0 0 50.0 50.0 50.0 100 100 100 50.0
Total 20.0 50.0 60.0 50.0 50.0 60.0 40.0 50.0 70.0 60.0 100 100 80.0 60.0
Serratia
Young-old 20.0 60.0 80.0 80.0 40.0 40.0 60.0 40.0 60.0 40.0 100 100 60.0 40.0
Old-old 16.7 33.3 16.7 16.7 66.7 66.7 66.7 50.0 50.0 50.0 100 83.3 50.0 33.3
Oldest-old 0 0 0 0 100 100 100 100 0 0 100 100 0 0
Total 16.7 41.7 41.7 41.7 58.3 58.3 66.7 50.0 50.0 41.7 100 91.7 50.0 33.3

AMP: ampicillin, AC: amoxicillin/clavulanic acid, PT: piperacillin/tazobactam, CP: cefepime, CT: cefotaxime, CTZ: ceftazidime, CZ: cefazolin, CX: cefoxitin, GM: gentamicin, CF: ciprofloxacin, EP: ertapenem, IP: imipenem, AK: amikacin, TS: trimethoprim/sulfamethoxazole.

  • 1. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol 2003;13:144-50. PubMed
  • 2. Brown PD. Antibiotic selection for urinary tract infection: new microbiologic considerations. Curr Infect Dis Rep 1999;1:384-8. ArticlePubMedPDF
  • 3. Czaja CA, Scholes D, Hooton TM, Stamm WE. Popula-tion-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007;45:273-80. ArticlePubMed
  • 4. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-81. ArticlePubMed
  • 5. Ki M, Park T, Choi B, Foxman B. The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol 2004;160:985-93. ArticlePubMed
  • 6. Kim B, Myung R, Kim J, Lee MJ, Pai H. Descriptive epide-miology of acute pyelonephritis in Korea, 2010-2014: population-based study. J Korean Med Sci 2018;33:e310. ArticlePubMedPMCPDF
  • 7. Hsu CY, Fang HC, Chou KJ, Chen CL, Lee PT, Chung HM. The clinical impact of bacteremia in complicated acute pyelone-phritis. Am J Med Sci 2006;332:175-80. ArticlePubMed
  • 8. Lee JH, Lee YM, Cho JH. Risk factors of septic shock in bacteremic acute pyelonephritis patients admitted to an ER. J Infect Chemother 2012;18:130-3. ArticlePubMed
  • 9. Tambo M, Okegawa T, Shishido T, Higashihara E, Nutahara K. Predictors of septic shock in obstructive acute pyelonephritis. World J Urol 2014;32:803-11. ArticlePDF
  • 10. Yamamoto Y, Fujita K, Nakazawa S, Hayashi T, Tanigawa G, Imamura R, et al. Clinical characteristics and risk factors for septic shock in patients receiving emergency drainage for acute pyelonephritis with upper urinary tract calculi. BMC Urol 2012;12:4. ArticlePubMedPMCPDF
  • 11. Wie SH, Ki M, Kim J, Cho YK, Lim SK, Lee JS, et al. Clinical characteristics predicting early clinical failure after 72 h of antibiotic treatment in women with community-onset acute pyelonephritis: a prospective multicentre study. Clin Microbiol Infect 2014;20:O721-9. ArticlePubMed
  • 12. Kunin CM. Urinary tract infections: detection, prevention, and management. 5th ed. Williams & Wilkins; 1997. Baltimore.
  • 13. Efstathiou SP, Pefanis AV, Tsioulos DI, Zacharos ID, Tsiakou AG, Mitromaras AG, et al. Acute pyelonephritis in adults: prediction of mortality and failure of treatment. Arch Intern Med 2003;163:1206-12. ArticlePubMed
  • 14. Min HJ. Acute pyelonephritis: clinical study and consideration about inpatient therapy. Korean J Med 1998;55:232-44.
  • 15. Nicolle LE. Epidemiology of urinary tract infections. Clin Microbiol Newsl 2002;24:135-40. Article
  • 16. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001;183 Suppl 1:S1-4. ArticlePubMed
  • 17. Kim WB, Cho KH, Lee SW, Yang HJ, Yun JH, Lee KW, et al. Recent antimicrobial susceptibilities for uropathogenic esche-richia coli in patients with community acquired urinary tract infections: a multicenter study. Urogenit Tract Infect 2017;12:28-34. ArticlePDF
  • 18. Eveillard M, Pisante L, Mangeol A, Dolo E, Guet L, Huang M, et al. Specific features of nosocomial infections in the elderly at a general hospital center. 5 surveys of annual prevalence. Pathol Biol (Paris) 1998;46:741-9; French.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • ePub LinkePub Link
      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Clinical Characteristics and Antimicrobial Susceptibility of Elderly Women with Acute Pyelonephritis
        Urogenit Tract Infect. 2020;15(3):71-78.   Published online December 31, 2020
        Close
      • XML DownloadXML Download
      Clinical Characteristics and Antimicrobial Susceptibility of Elderly Women with Acute Pyelonephritis
      Clinical Characteristics and Antimicrobial Susceptibility of Elderly Women with Acute Pyelonephritis

      Clinical characteristics and laboratory findings of elderly women with acute pyelonephritis

      Characteristic Young-old (65-74) Old-old (75-84) Oldest-old (>85) p-value
      Number 176 142 42
      Age (y) 69.9±2.7 79.4±3.1 87.3±3.1 <0.05a)
      Clinical progress
      Days of hospitalization 7.0±1.7 7.8±2.6 12.6±2.9 <0.05a)
      Duration of fever 3.2±1.0 3.8±0.8 5.1±1.6 <0.05a)
      Peak fever (°C) 39.0±1.2 39.3±0.9 39.0±0.6 0.061a)
      Laboratory findings
      White blood cell 16,811.4±4,888.4 17,833.5±5,516.8 17,775.5±6,066.0 0.196a)
      ESR 97.1±20.3 107.0±25.2 109.7±30.5 <0.05a)
      C-reactive protein 11.6±4.7 13.3±5.0 15.7±5.2 <0.05a)
      Urine RBC 119 (67.6) 92 (64.8) 26 (61.9) 0.739b)
      Comorbidity
      Diabetes mellitus 48 (27.3) 51 (35.9) 14 (33.3) 0.245b)
      Cerebrovascular disorder 25 (14.2) 35 (24.6) 12 (28.6) <0.05b)
      Congestive heart failure 15 (8.5) 25 (17.6) 14 (33.3) <0.05lb)
      Chronic kidney disease 13 (7.4) 21 (14.8) 3 (7.1) 0.075b)
      Chronic liver disease 10 (5.7) 17 (12.0) 4 (9.5) 0.135b)
      Chronic lung disease 25 (14.2) 32 (22.5) 5 (11.9) 0.092b)
      Malignancy 19 (10.8) 12 (8.5) 2 (4.8) 0.443b)
      Neurogenic bladder 32 (18.2) 19 (13.4) 5 (11.9) 0.394b)
      Stone disease 25 (14.2) 34 (23.9) 13 (31.0) <0.05b)
      Catheter indwelling 17 (9.7) 17 (12.0) 6 (14.3) 0.634b)
      Past history (within one year)
      Recent urinary tract infection 10 (5.7) 23 (16.2) 14 (33.3) <0.05b)
      Recent urologic manipulation 10 (5.7) 8 (5.6) 2 (4.8) 0.972b)
      Presence of cUTI factors 98 (55.7) 86 (60.6) 25 (59.5) 0.667b)

      Values are presented as number only, mean±standard deviation or number (%).

      ESR: erythrocyte sedimentation rate, RBC: red blood cell, cUTI: complicated urinary tract infection.

      a)Analysis of variance. b)Pearson chi-square test.

      Distribution of uropathogens by age

      Organism Total Young-old (65-74) Old-old (75-84) Oldest-old (>85)
      Gram-negative
      Escherichia coli 213 (59.2) 113 (64.2) 82 (57.8) 18 (42.9)
      Klebsiella 45 (12.5) 23 (13.1) 17 (12.0) 5 (11.9)
      Proteus 17 (4.7) 8 (4.6) 5 (3.5) 4 (9.5)
      Pseudomonas 15 (4.2) 6 (3.4) 6 (4.2) 3 (7.1)
      Enterobacter 15 (4.2) 5 (2.8) 6 (4.2) 4 (9.5)
      Serratia 12 (3.3) 5 (2.8) 6 (4.2) 1 (2.4)
      Citrobacter 10 (2.8) 4 (2.3) 4 (2.8) 2 (4.8)
      Gram-positive
      Staphylococcus 13 (3.6) 5 (2.8) 6 (4.2) 2 (4.8)
      Streptococcus 11 (3.1) 4 (2.3) 5 (3.5) 2 (4.8)
      Enterococcus 9 (2.5) 3 (1.7) 5 (3.5) 1 (2.4)

      Values are presented as number (%).

      Antimicrobial susceptibility of uropathogens from elderly women with acute pyelonephritis

      Antimicrobial Susceptibility p-value

      Young-old (65-74) Old-old (75-84) Oldest-old (>85)
      Ampicillin 57/174 (32.8) 40/138 (29.0) 11/42 (26.2) 0.626
      Cefepime 119/175 (68.0) 88/136 (64.7) 23/36 (63.9) 0.789
      Cefotaxime 123/176 (69.9) 92/142 (64.8) 29/42 (69.0) 0.615
      Ceftazidime 127/176 (72.2) 102/140 (72.9) 28/40 (70.0) 0.939
      Gentamicin 119/168 (70.8) 107/142 (75.4) 31/42 (73.8) 0.666
      Cefazolin 119/174 (68.4) 79/141 (56.0) 21/39 (53.8) <0.05
      Ertapenem 169/170 (99.4) 135/142 (95.1) 37/39 (94.9) <0.05
      Piperacillin/tazobactam 156/173 (90.2) 119/139 (85.6) 30/37 (81.1) 0.229
      Amoxicillin/clavulanic acid 111/176 (63.1) 86/135 (63.7) 24/39 (61.5) 0.969
      Amikacin 167/172 (97.1) 131/143 (91.6) 33/39 (84.6) <0.05
      Cefoxitin 153/176 (86.9) 106/142 (74.6) 28/40 (70.0) <0.05
      Ciprofloxacin 120/176 (68.2) 82/141 (58.2) 20/42 (47.6) <0.05
      Imipenem 172/176 (97.7) 131/142 (92.3) 38/42 (90.5) <0.05
      Trimethoprim/sulfamethoxazole 107/176 (60.8) 89/141 (63.1) 26/42 (61.9) 0.914

      Values are presented as number (%).

      Antimicrobial susceptibility according to age/uropathogens

      Organism Antibiotics susceptibility (%)

      AMP AC PT CP CT CTZ CZ CX GM CF EP IP AK TS
      Escherichia coli
      Young-old 18.6 53.1 57.5 46.0 61.9 75.2 28.3 58.4 65.5 72.6 99.1 99.1 80.5 79.6
      Old-old 22.0 24.4 41.5 50.0 64.6 58.5 45.1 22.0 73.2 67.1 97.6 97.6 68.3 51.2
      Oldest-old 22.2 33.3 38.9 33.3 55.6 77.8 44.4 16.7 72.2 66.7 94.4 94.4 66.7 38.9
      Total 20.2 40.4 49.8 46.5 62.4 69.0 36.2 40.8 69.0 70.0 98.1 98.1 74.6 65.3
      Klebsiella
      Young-old 8.7 47.8 60.9 65.2 56.5 52.2 69.6 56.5 56.5 65.2 100 100 73.9 65.2
      Old-old 11.8 70.6 76.5 70.6 64.7 58.8 58.8 41.2 47.1 70.6 100 100 70.6 41.2
      Oldest-old 20.0 20.0 40.0 40.0 60.0 80.0 40.0 20.0 40.0 80.0 80.0 100 60.0 20.0
      Total 11.1 53.3 64.4 64.4 60.0 57.8 62.2 46.7 51.1 68.9 97.8 100 71.1 51.1
      Proteus
      Young-old 50.0 12.5 62.5 37.5 87.5 87.5 37.5 62.5 87.5 75.0 100 100 87.5 75.0
      Old-old 40.0 40.0 40.0 60.0 80.0 60.0 20.0 60.0 80.0 60.0 100 100 60.0 60.0
      Oldest-old 50.0 25.0 25.0 25.0 50.0 75.0 75.0 25.0 75.0 50.0 100 100 50.0 75.0
      Total 47.1 23.5 47.1 41.2 76.5 76.5 41.2 52.9 82.4 64.7 100 100 70.6 70.6
      Pseudomonas
      Young-old 0 66.7 50.0 66.7 16.7 66.7 16.7 16.7 33.3 33.3 66.7 83.3 50.0 16.7
      Old-old 0 33.3 16.7 33.3 33.3 83.3 16.7 33.3 16.7 50.0 83.3 83.3 66.7 16.7
      Oldest-old 33.3 33.3 0 0 33.3 33.3 0 66.7 33.3 33.3 66.7 66.7 33.3 0
      Total 6.7 46.7 26.7 40.0 26.7 66.7 13.3 33.3 26.7 40.0 73.3 80.0 53.3 13.3
      Enterobacter
      Young-old 20.0 80.0 60.0 60.0 80.0 80.0 80.0 60.0 80.0 80.0 100 100 80.0 60.0
      Old-old 16.7 50.0 33.3 66.7 66.7 83.3 83.3 33.3 83.3 83.3 100 100 66.7 83.3
      Oldest-old 25.0 75.0 50.0 25.0 50.0 75.0 25.0 50.0 50.0 75.0 100 100 50.0 25.0
      Total 20.0 66.7 46.7 53.3 66.7 80.0 66.7 46.7 73.3 80.0 100 100 66.7 60.0
      Citrobacter
      Young-old 25.0 75.0 75.0 25.0 50.0 50.0 75.0 50.0 75.0 50.0 100 100 75.0 75.0
      Old-old 0 25.0 50.0 75.0 50.0 75.0 25.0 50.0 75.0 75.0 100 100 75.0 50.0
      Oldest-old 50.0 50.0 50.0 50.0 50.0 50.0 0 50.0 50.0 50.0 100 100 100 50.0
      Total 20.0 50.0 60.0 50.0 50.0 60.0 40.0 50.0 70.0 60.0 100 100 80.0 60.0
      Serratia
      Young-old 20.0 60.0 80.0 80.0 40.0 40.0 60.0 40.0 60.0 40.0 100 100 60.0 40.0
      Old-old 16.7 33.3 16.7 16.7 66.7 66.7 66.7 50.0 50.0 50.0 100 83.3 50.0 33.3
      Oldest-old 0 0 0 0 100 100 100 100 0 0 100 100 0 0
      Total 16.7 41.7 41.7 41.7 58.3 58.3 66.7 50.0 50.0 41.7 100 91.7 50.0 33.3

      AMP: ampicillin, AC: amoxicillin/clavulanic acid, PT: piperacillin/tazobactam, CP: cefepime, CT: cefotaxime, CTZ: ceftazidime, CZ: cefazolin, CX: cefoxitin, GM: gentamicin, CF: ciprofloxacin, EP: ertapenem, IP: imipenem, AK: amikacin, TS: trimethoprim/sulfamethoxazole.

      Table 1 Clinical characteristics and laboratory findings of elderly women with acute pyelonephritis

      Values are presented as number only, mean±standard deviation or number (%).

      ESR: erythrocyte sedimentation rate, RBC: red blood cell, cUTI: complicated urinary tract infection.

      a)Analysis of variance. b)Pearson chi-square test.

      Table 2 Distribution of uropathogens by age

      Values are presented as number (%).

      Table 3 Antimicrobial susceptibility of uropathogens from elderly women with acute pyelonephritis

      Values are presented as number (%).

      Table 4 Antimicrobial susceptibility according to age/uropathogens

      AMP: ampicillin, AC: amoxicillin/clavulanic acid, PT: piperacillin/tazobactam, CP: cefepime, CT: cefotaxime, CTZ: ceftazidime, CZ: cefazolin, CX: cefoxitin, GM: gentamicin, CF: ciprofloxacin, EP: ertapenem, IP: imipenem, AK: amikacin, TS: trimethoprim/sulfamethoxazole.


      Urogenit Tract Infect : Urogenital Tract Infection
      Close layer
      TOP